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ABSTRACT 
 
DC-SIGN a DC-specific C-type lectin is a receptor highly expressed on dendritic cells 
surface and it has the ability to bind a great number of pathogens, recognizing a mannose- 
and fucose- containing glycans through its terminal carbohydrate recognition domain 
(CRD). DC-SIGNs also bind different types of viruses, such as the HIV-1, interacting via 
HIV-1 envelope glycoprotein gp120. The main natural ligand recognized by DC-SIGN is 
the high mannose glycan, (Man)9(GlcNAc)2 or (Man9), a branched oligosaccharide 
presented in multiple copies by several pathogen glycoproteins, as well as the HIV 
envelope glycoprotein gp120. All Man9 branches are composed by a terminal 
disaccharide portion, Manα1-2Man, involved in high mannose recognition process by 
DC-SIGN receptor. High-density arrays of unbranched Manα1-2Man-terminated 
oligosaccharides bind DC-SIGN almost as efficiently as the entire Man9. 
Recently in our laboratory was synthesized a new DC-SIGN antagonist as mimics of the 
natural Manα1-2Man. The latter is composed by two moieties: the nonreducing unit 
formed by a mannose anchor, as Manα1-2Man, and the reducing one, where the mannose 
was substituted by a real D-carbamannose core, that attributes more enzymatic stability 
to the pseudo-disaccharides. 
The antagonist was tested using an infection model based on Ebola envelope pseudotyped 
viruses and Jukart cells expressing DC-SIGN. The results demonstrated an IC50 values 
slightly higher than the natural ligand, probably due to the high polar portions present on 
the carbamannose core.  
In view of this the main purpose of this thesis project is the stereoselective synthesis of 
the new pseudo-disaccharide as DC-SIGN antagonist, with a real D-carbamannose core 
and a methyl group at C(5) position instead of hydroxy-methylene group. The methyl 
group has the aim to increase the cyclohexane ring lipophilicity and, consequently, the 
interaction between the antagonist and the DC-SIGN binding site. In this way, we 
hypotesize to increase the inhibitory activity of the antagonist. 
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1. INTRODUCTION 
 
1.1 Dendritic cells[1]  
Dendritic cells (DCs) are a family of bone marrow derived antigen-presenting cells 
(APCs) with a capacity to interact with T cells and modulate their responses. DCs are 
found in most nonlymphoid organs, including epithelia (e.g. the epidermis and mucosa, 
where DCs are called Langerhans). DCs are also found in blood, lymph and in all 
lymphoid organs where, in the T cell area they interact with T cells. In the bone marrow 
the steam cells differentiate and subsequently migrate as precursor DC into the blood and 
from there into tissues to monitor these tissues against invading pathogens (Fig. 1.1). 
Upon entry, pathogens are sampled by immature DC, resulting in maturation and 
migration of the maturing DC through the lymph into the lymphoid tissues. Pathogen-
derived antigens are presented by the mature DC to resting T cells, and antigen-specific 
T cells are activated. These T cells proliferate and migrate into the compromising tissues 
to perform their effector functions.  
 
 
Fig. 1.1: Role of DC in the immune system. 
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1.2 DC-T cells interaction 
The initial contact between DC and resting T cells, necessary for T cell activation, is 
established and regulated by chemokines and adhesion molecules. Chemokines control 
the differentiation stages of the DC and, once in the T cell area of lymph nodes, attract 
resting T cells toward the DC. Adhesion molecules enable the establishment of contact 
between resting T cell and DC, providing sufficient stability to allow scanning of the 
MHC class II-peptide complex and to induce T cell receptor triggering. 
 Several studies have suggested that ICAM-3, a member of the immunoglobulin (Ig) 
superfamily which is expressed at high levels on resting T cells, might be important in 
establishing these initial DC-T cell interactions[2-3-4]. Separate from mediating adhesion 
between DC and T cells, ICAM-3 may be important also in providing signals necessary 
for efficient T cell activation. The β2 integrins LFA-1 (αLβ2) and αDβ2 have both been 
described as the primary receptors for ICAM-3, although the affinity of both integrins for 
ICAM-3, even after integrin activation, is rather low. Because LFA-1 is expressed by DC 
and anti-LFA-1 antibodies partially inhibit DC-T cell interactions, it potentially mediates 
binding of resting T cells through ICAM-3. However, the multitude of adhesion receptors 
and ligands that simultaneously contribute to the DC-T cell contacts form a major obstacle 
in antibody blocking studies to dissect the individual role of each adhesion receptor. 
 Geijtenbeek et al. in the 2000 developed an adhesion assay which allow them to 
specifically address the role of ICAM-3 in DC-T cell interactions[2]. They discovered that 
neither LFA-1 nor αDβ2 but a novel ICAM-3 binding C-type lectin, exclusively 
expressed by DC, mediates strong adhesion between DC to ICAM-3 on resting T cells 
and is essential for DC-induced T cell proliferation. Interestingly, though the interaction 
is integrin independent it requires the presence of Ca2+, as both EDTA and EGTA are 
inhibitory (Geijtenbeek et al., 2000[2]). From these observations they designated this 
receptor DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN).  
The natural ligand of DC-SIGN on lymphocytes, ICAM-3, contains N-linked 
glycosylations consisting of high mannose-type oligosaccharides, and, enzymatic 
removal of N-linked carbohydrates from ICAM-3 abrogates its binding to DC-SIGN 
completely[6]. Besides the inhibition of DC-SIGN function by mannan suggest that its 
interaction with the ligands is mediated by mannose-like carbohydrates. 
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 Apart ICAM-3, DC-SIGN binds ICAM-2 but not ICAM-1, two other members of the Ig 
superfamily. However, DC-SIGN interacts with ICAM-2 differently from that with 
ICAM-3. The distinct carbohydrate structure and/or the different size of the ICAM 
molecules may determine the manner of interaction. ICAM-2 plays a central role in 
mediating leukocyte recirculation as well as homing into secondary lymphoid tissues and, 
it is expressed on the endothelium of blood and lymphatic vessels as well as on high 
endothelial vascular cells and leukocytes. 
 
1.3 C-type lectins 
C-type lectins are probably the largest family of lectins and, they are involved in a diverse 
range of functions including cell-cell adhesion, immune response to pathogens and 
apoptosis. The C-type designation is from their requirement for calcium for binding. C-
type lectins have in common a domain, named C-type lectin-like domain (CTLD) or 
carbohydrate recognition domain (CRD). It is a compact globular structure responsible 
for selective binding of terminal units found in large carbohydrates[7]. The main structural 
hallmark of such a domain is that it binds a carbohydrate by Ca2+ ion, which acts as a 
bridge between the protein and the core monosaccharide unit through complex 
interactions with sugar hydroxyl groups[8]. The binding with Ca2+ ion involves just one 
terminal saccharide unit, while other ligand carbohydrates units (if present) form 
structural and bonding complementarity with the CRD.  
Many C-type lectins have been identified on DC: Type I multi-CRD lectins are 
represented by the mannose receptor (MR) and DEC-205, and the most important type II 
single-CRD lectins, by DC-SIGN and Langerin. C-type lectins expressed by DC have 
specificity form mannose-containing carbohydrates; however, each C-type lectin may 
recognize a unique branching and positioning of mannose residues on a given pathogen 
or cell-surface structure. For example, the MR recognizes branch-end mannose residues, 
whereas DC-SIGN recognizes high-mannose residues located more internally within a 
glycan structure[9]. Most C-type lectins on DC are pathogen recognition receptors that 
capture and deliver pathogens or their fragments into the antigen processing 
compartments that permit MHC class II restricted presentation. Anyway C-type lectins 
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are not expressed exclusively on DC but are also expressed by other antigen-presenting 
cell (APC) such as macrophages. 
 
1.4 The dual function of DC-SIGN  
DC-SIGN is a member of the C-type lectin receptors (CLRs) that acts as adhesion 
receptor, through ICAM-3 binding, allowing interaction between DCs and resting T cells. 
Besides the ICAM-3 binding, probably the most important feature of DC-SIGN is its 
ability to bind a great number of important pathogens. This is possible due to its ability 
to recognize mannose- and fucose-containing glycans, through CRD domain, which are 
differentially expressed on a number of bacteria, parasites and viruses[9-10-11].  
On mucosal surfaces, where immature dendritic cells sample pathogens, DC-SIGN serves 
as one of the very first pathogen attachment points and the result of this interaction is 
pathogen internalization, degradation and exposure of the pathogen PAMPs to recruit 
CD4+ T-cells and to start the humoral immune response. DC-SIGN can also function as 
an endocytic receptor, through the dileucine motif in the cytoplasmic tail, in fact the 
binding of soluble ligand to the receptor induces rapid internalization from the cell surface 
and accordingly, DC-SIGN-ligand complexes are targeted to lysosomal compartments 
where ligands are processed for MHC class II presentation to T cell. This indicating an 
important function for DC-SIGN as antigen receptor. 
 The dual role of DC-SIGN as adhesion receptor and Ag receptor provides DCs with a 
functional receptor throughout their life span. The two different functions do not 
necessarily affect each other, indeed Ag internalization through DC-SIGN does not affect 
ICAM-3 binding and vice versa. 
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1.5 DC-SIGN a novel HIV-1 receptor  
DC-SIGN modulate the outcome of the immune response of DCs by binding and 
recognizing a variety of microorganisms, including viruses such as HIV-1. In particular, 
HIV-1 exploits native DC-SIGN functions to develop a totally dispersed infection in 
process called trans-infection, where DCs are used as carriers to boost T cell infection 
without becoming infected themselves. HIV-1 is carried by DCs from mucosal surfaces 
and blood to lymphoid tissues, where it primarily infects CD4+ T cells. The first 
interaction between HIV-1 and DCs occurs via HIV-1 envelope glycoprotein gp120 with 
DC-SIGN on immature DCs. The HIV-1-DC-SIGN complex is promptly internalized to 
the endosomes, in where the acidic medium causes ligands to dissociate from DC-SIGN. 
After dissociation, most DC-SIGN-bound ligands are lyzed and processed (a normal 
degradation pathway), but HIV-1 remains bound to DC-SIGN and the small amount of 
HIV-1 that enters DCs remain protected from the host immune system and retains its 
infectiveness (Fig. 1.2). HIV-1 resides in DCs in an infectious state for days, hidden in 
multivesicular bodies that differ from both endosomes and lysosomes[12]. All the factors 
that influence whether HIV-1 virus is degraded or transmitted to T cells remain 
undisclosed till today. However, van Montfort et al. have recently discovered that HIV-1 
N-glycan composition governs the viral faith upon interaction of viral envelope with DC-
SIGN[5].  
 
Fig. 1.2: DC-SIGN rule in HIV infection.              Fig. 1.3: Different binding sites in the DC-SIGN CRD. 
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Anyway HIV-1 uses DC-SIGN as an entry mode to DCs, and DCs may be regarded as 
Trojan horse that takes HIV-1 to CD4+ T cells while protecting it from the host immune 
system.  
Apart from this straightforward infection pathway, HIV-1-infected DCs are able to 
mediate transmission of HIV-1 to CD4+ cells by means of immune response modulation 
and infectious synapse formation. Namely, HIV-1 causes both inhibition of DC 
maturation while inducing formation of viral synapse, a process previously attributed to 
mature DCs only[13]. Interestingly, that the Nef protein of HIV-1 affects the intracellular 
trafficking of DC-SIGN (Fig. 1.2). Nef is crucial for viral replication, including DC-T 
cell binding. Expression of Nef in immature DC results in a redistribution of DC-SIGN 
to the cell surface, thus reducing DC-SIGN internalization in favor of cell surface 
expression and facilitating increased cell adhesion and virus transmission T cells. 
Redistribution of DC-SIGN requires the dileucine motif in the cytoplasmic tail of DC-
SIGN as well as a dileucine motif in Nef, indicating that Nef interferes recognition of 
DC-SIGN by the sorting machinery[14].  
 
1.5.1 Two distinct binding sites for gp120 and ICAM 
The HIV-1 envelope glycoprotein gp120 is heavily glycosylated and contains high 
mannose-type oligosaccharides. Strikingly, although glycosylation seems to enhance the 
affinity of gp120 binding, neither O- nor N-linked glycosylations are vital for the 
interaction of HIV-1 gp120 with DC-SIGN, as DC-SIGN interacts with enzymatically 
deglycosylated and nonglycosylated gp120[6]. Therefore, the interaction of DC-SIGN 
with gp120 differs from that with ICM-3, indicating different binding sites for ICM-3 and 
HIV-1 gp120 in DC-SIGN. The three-dimensional structure of DC-SIGN shows that the 
Val351 residue in DC-SIGN participates in carbohydrate binding through van der Waals’ 
interactions (Fig. 1.3). This Val351 is important because denotes the difference between 
the interaction of DC-SIGN with gp120 and ICAM-3[6]. Indeed, the Val351 residue is 
important in binding carbohydrates and ICAM-3, but it is not essential for gp120 binding 
as the Val351 G mutant of DC-SIGN still interacts with gp120 but is unable to bind 
ICAM-3[6]. Thus the interaction of DC-SIGN with ICAM-3, in contrast with that of 
gp120, is carbohydrate-dependent. The different binding sites in human DC-SIGN for 
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ICAM-3 and gp120 are attractive targets for therapeutic intervention of DC-induced 
immunity and HIV-1 dissemination by DC-SIGN, respectively. 
 
1.6 DC-SIGN structure 
DC-SIGN is a type II lectin that containing one CRD, a globular structure consisting of 
12 β-strands, two α-helices and three disulphide bridges (Fig. 1.4). A loop protrudes from 
the protein surface and forms part of two Ca2+-binding sites that are responsible for the 
conformation of the CRD and essential for direct formation of coordinate bonds with the 
carbohydrate structures. Besides the carboxy-terminal CRD, DC-SIGN contains a neck 
region composed of seven complete and one incomplete tandem repeats, and a 
transmembrane region followed by a cytoplasmic tail (Fig. 1.5). The cytoplasmic tail 
contains several motifs that may direct its intracellular targeting: a tyrosine based motif 
(Y-based), a triacidic cluster (EEE) and a dileucine motif (LL).  
                             
 
 
 
 
 
 
 
 
Fig. 1.4: DC-SIGN CRD crystal structure (PDB 1SL4).      Fig. 1.5: DC-SIGN schematic structure.  
 
The dileucine motif (LL) supports internalization of DC-SIGN-ligand complex from the 
cell surface in transfected cells, while a dual role has indicated for the EEE motif as a 
sorting signal in the secretory pathway and lysosomal targeting signal in the endocytic 
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pathway. Like many C-type lectins, DC-SIGN tetramerizes to increase binding affinity. 
The oligomerization occurs through association of the DC-SIGN neck domains and 
depends on the number of helical repeats in each member of the neck region; at least 6 
repeats are needed for tetramerization. The CRD of tetramerized DC-SIGN provides the 
means of increasing the specificity for multiple repeating units on host molecules, thereby 
defining the set of pathogens that are recognized by DC-SIGN.  
DC-SIGN neck domain, besides allowing tetramerization, plays a central role of a pH-
sensor that balances the equilibrium between the monomeric and tetrameric states of DC-
SIGN[15]. In this sense, affinity for carbohydrates may be changed markedly by changing 
the pH, which regulates pathogen release in acidic endosomal environment where 
pathogen degradation takes place. Another important function of the neck domain is to 
stabilize the CRDs and separate them from the cell surface to enable multivalent 
interaction with glycan ligands. 
 Apart from tetramerization, DC-SIGN is found in different levels of organization, i.e. 
clustering in microdomains (Fig. 1.6). This organization of DC-SIGN in microdomains 
on the plasma membrane is important for the binding and internalization, suggesting that 
these multimolecular assemblies act as docking sites for pathogens. DC-SIGN is not a 
totally rigid macromolecule and shows a degree of flexibility upon ligand binding. 
Namely, DC-SIGN adapts to an arrangement of terminal oligo- and monosaccharides, so 
all CRDs are allowed to interact with their ligands. Taken together, the tetrameric form 
of DC-SIGN and its conformational flexibility enable effective and selective binding of 
various glycans. 
                                                                             
 
 
 
 
 
Fig. 1.6: DC-SIGN tetramerization through association of the neck domains. 
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1.7 DC-SIGN Vs. Langerin/Mannose receptor selectivity  
DC-SIGN is supposed to be the major attachment point for various pathogen, especially 
HIV-1, but other C-type lectins might be equally important for HIV-1 binding onto 
various subtypes of DCs. Langerin on epithelial Langerhans cells and a mannose receptor 
on dermal DCs both bind high-mannose oligosaccharides and HIV-1 gp120 with high 
affinity. The outcome of HIV-DC interaction appears to differ according to the C-type 
lectin involved. Langerin is a C-type lectin specific for Langerhans cells and induces the 
formation of Birbeck granules. While interaction of HIV-1 with DC-SIGN enables HIV-
1 to survive a host immune system, Langerin mediates HIV-1 internalization into Birbeck 
granules where viral particles are degraded[16]. In contrast, mannose receptor may 
facilitate HIV-1 entry into DC cytoplasm.  
Therefore, blockade of both DC-SIGN and mannose receptor might prevent HIV-1 entry 
into DCs whereas HIV-1 binding to Langerin does not enhance HIV-1 infection, but 
rather prevents T cell infection by viral clearance. Consequently, Langerin inhibition has 
a deleterious effect on viral clearance and allows HIV-1 infection[16]. An agent that would 
prevent HIV-1 from entering DCs should thus inhibit both DC-SIGN and mannose 
receptor, while retaining selectivity against Langerin. This might seem to be an 
insurmountable barrier to overcome, as all three receptors bind virtually the same ligands. 
However, selectivity against Langerin might be obtained, as its binding site differs from 
that of DC-SIGN. 
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1.8 The binding site of DC-SIGN 
Understanding the mechanism of ligand binding to DC-SIGN CRD is crucial for the 
development of specific antiviral DC-SIGN antagonist. As a C-type lectin, DC-SIGN 
binds carbohydrate ligands in a Ca2+ dependent manner. Its CRD binding site offers 6 
coordination bonds for a Ca2+ ion, and 2 additional coordination bonds formed with the 
carbohydrate residue. DC-SIGN contains several amino acids sequences in its CRD-
binding region, which discloses a preference for binding to monosaccharides, with the 
hydroxyls in positions 3 and 4 in the equatorial orientation. The equatorial 3- and 4-
hydroxyls each form not only coordination bonds with the Ca2+, but also hydrogen bonds 
with amino acids that also serve as Ca2+ ligands. Accordingly, the Ca2+ is octacoordinated 
with 3 carboxylate moieties (Glu347, Glu354, Asp366), 2 side-chain carbonyls (Asn349, 
Asn365) one backbone carbonyl (Asp366) and two hydroxyls from the carbohydrate 
residue.  
DC-SIGN binds various monosaccharides, but has the highest affinity for L-fucose and 
D-mannose, however the binding of monovalent carbohydrate to DC-SIGN CRD is 
generally very weak, indeed Guo et al. demonstrate that high-mannose and fucosylated 
oligosaccharides bind to DC-SIGN CRD with moderate affinity[17]. Further evidence is 
the DC-SIGN tetramerization which increases the binding affinity of ligands composed 
of repetitive sugar moieties. DC-SIGN binding site is unique since it involves Ca2+ 
complexing with an internal α1-3 linked Man3 (PDB structure of DC-SIGN CRD 
complexed with Man4[17]) rather than a terminal mannose moiety[18]. This is a direct 
consequence of the steric hindrance formed by the Phe313 phenyl ring, which fits into 
the gap between Man1 and Man4, where it makes van der Waals contacts with the central 
Man3. Particularly the Phe313 residue hinders linear oligosaccharide binding, so 
branched oligosaccharides are accommodated instead of the linear ones[18-19]. 
Interestingly which there are affinity differences between mannose- and fucose-based 
ligands, resulting from different spatial arrangement, as seen in the crystal structure of 
fucose-based oligosaccharide LNFP III and Man4 bound to DC-SIGN[17]. The Man3 
mannose moiety (in complex with Ca2+) inclines the rest of the molecule towards Phe313 
with high surface complementarity (Fig. 1.7d), while the fucose moiety makes 
hydrophobic contact with Val351 and positions the second saccharide in a vertical 
manner, away from the protein surface (Fig. 1.7a and 1.7b). This allows fucosylated 
Introduction 
16 
 
oligosaccharides to occupy the secondary binding site and indicates that mannose- and 
fucose-based ligands have overlapping, but different binding modes. The observed 
difference in biding mode might offer a rational explanation for the different biological 
effects of mannose- and fucose-based ligands[20].  
The binding mode presented for Man4 (Fig. 1.7c and 1.7d) is a prevalent one for 
mannose-containing oligosaccharides, however several other PDB structures of DC-
SIGN CRD show that Phe313 residue is rather flexible and allows 2 distinct binding 
modes, both including coordination with Ca2+ by one mannose residue. In the second 
binding mode, the orientation of the mannose at the principal Ca2+ site is reversed, and 
creates different interactions between the nonreducing terminal mannose and the region 
around Phe313[19].  
 
Fig. 1.7: DC-SIGN interactions with fucosylated and high-mannose oligosaccharides. 
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Another crucial structural feature of mannose residue is the axial position of the 2-
hydroxyl group; this allows tight surface complementarity of the core mannose with the 
binding site. Equatorial position of the 2-hydroxyl group would probably prevent this 
tight binding due to steric clash, so the mannose residue with equatorial 2-hydroxyl 
groups do not form strong interactions with the binding site.  
Based on the previous observations, we can conclude that only polyvalent ligands could 
efficiently bind to DC-SIGN, offering a rationale for design of multivalent carbohydrate 
systems as DC-SIGN antagonists. 
 
1.9 DC-SIGN antagonists designed to block DC-SIGN-
pathogen interaction    
Inhibition of the interaction of DC-SIGN-pathogen surface glycan or glycoproteins with 
DC-SIGN antagonists is considered to be a promising route towards new antimicrobial 
drugs. Unfortunately, interaction between DC-SIGN and monosaccharide results in only 
poor to modest binding affinity. Indeed, the usual nano- or micromolar affinities seen for 
the majority of therapeutically useful compounds are replaced by millimolar affinities 
when dealing with most monosaccharide-C-type lectin interactions. The high polarity of 
carbohydrates which is a warranty for poor pharmacokinetic proprieties of potential 
carbohydrate-derived drugs, has also to be considered. Even if the pharmacokinetic 
properties of carbohydrate-derived DC-SIGN antagonists are not an issue, the design of 
therapeutically useful DC-SIGN antagonist is still a challenging task.  
To cope with it, three main strategies have been used in designing selective and potent 
DC-SIGN antagonists: 
 The design of monovalent glycomimetics based on the DC-SIGN-binding 
oligosaccharide. 
 Multimeric presentation of monosaccharides/oligosaccharide or glycomimetics. 
 Screening of compound libraries to obtain non-carbohydrate DC-SIGN 
antagonists.  
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1.10 Monovalent glycomimetics as DC-SIGN antagonists 
The main natural ligand recognized by DC-SIGN is the high mannose glycan, 
(Man)9(GlcNAc)2 also represented as (Man9) (Fig. 1.8b), a branched oligosaccharide 
presented in multiple copies by several pathogen glycoproteins and specifically by the 
gp120 envelope protein of HIV. DC-SIGN can also recognize branched fucosylated 
structures bearing terminal galactose residues, such as the Lewis antigens[21] (Fig. 1.8a). 
They complex the Ca2+ ion on the DC-SIGN CRD, and offer the most important 
interaction with the DC-SIGN binding site. However, natural ligands containing mono- 
or oligo- and polysaccharides suffer from many disadvantages mentioned in previous 
section. To address their low activity and/or insufficient drug-like proprieties, 
glycomimetics compounds that mimic the bioactive function of carbohydrates are 
developed. 
 
 
Fig. 1.8: Chemical structure of Lewis X (a) and (Man)9(GlcNAc)2 (b) glycans. 
 
The design of glycomimetic DC-SIGN antagonists relies mainly on the use of either a 
fucose or a mannose anchor, therefore monovalent glycomimetic DC-SIGN antagonists 
could be divided into two subgroups according to the monosaccharide anchor used. 
However, shikimic acid was also used as an alternative anchor. The majority of 
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glycomimetic DC-SIGN antagonists resemble larger oligosaccharide structures, such as 
Lewis-type and high-mannose oligosaccharides, like (Man)9(GlcNAc)2.  
 
1.10.1 Fucose-based DC-SIGN antagonists  
Bernardi et al. designed monovalent α-fucosylamides as DC-SIGN antagonists based on 
the 3D structure of the Lewis-X trisaccharide (Fig. 1.9). In particular, the antagonist was 
designed using an α-fucosylamide anchor, which can drive the molecule to DC-SIGN 
primary binding site, and connecting it to a galactose mimic via a cyclic cis-β aminoacid 
linker. Amide bonds were chosen to connect the three elements of the molecule as a 
surrogate for the metabolically unstable α-glycosidic bond[22-23]. A second ligand was also 
prepared by substitution of the complex galactose mimic by a simple acetamide group. 
Both synthesized compounds had slightly higher affinities than the starting Lewis-X 
trisaccharide. The small difference in affinity between the antagonists 1.1 and 1.2 
suggested that the galactose mimic fragment in 1.1 gave a limited contribution to the 
binding interaction. This result revealed that only fucose residue makes strong contact 
with the DC-SIGN CRD and suggested to replace the galactose mimic 1.1 by other 
residues to optimize the interaction on the secondary binding site of the lectin[23]. 
  
 
 
 
 
 
 
 
(Timpano et al. (2008) ChemBioChem[23])       (Andreini et al. (2011) Org. Biomo. Chem.[22]) 
Fig. 1.9: Fucose-based DC-SIGN antagonists with their IC50 values. 
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Following this strategy, a second generation of fucose-based ligands was synthesized 
using as lead compound the fucosylamide 1.2. A library of 30 compounds of general 
formula 1.3a were synthesized with similar binding affinity to that of 1.2, independently 
of the nature of the R group[22]. 
 To examine the effect of the β-aminoacid linker structure on the activity of the ligands, 
a new group of molecules of general formula 1.4 was prepared, using a more flexible β-
alanine linker rather than (1S, 2R)-2-amino-cyclohexanecarboxylic acid. Interestingly, 
these simple α-fucosyl-β-alanyl amides showed a similar affinity to that of compound 1.2. 
This unexpected results confirmed that the (1S, 2R)-2-amino-cyclohexanecarboxylic acid 
scaffold selected for the synthesis of 1.2 does not enforce optimal interaction of the 
secondary residue with the binding site[23]. To further explore the role of the β-aminoacid 
structure, the configuration of the scaffold was changed systematically and a third set of 
compounds 1.3b-1.3d was synthesized, where the R fragment was kept unchanged and 
the β-aminoacid configuration was changed. The IC50 values of this set confirmed that 
the activity of most fucosylamides is close to that of Lewis-X[23].  
                                             
 
 
 
 
(Andreini et al. (2011) Org. Biomol. Chem.) 
Fig. 1.10: α-fucosyl-β-alanyl amide and a library of compounds with different stereochemistry. 
 
The highlight of these compounds in that none had any notable affinity for Langerin, even 
at the highest tested concentration. Their relatively low affinity for DC-SIGN, however, 
Introduction 
21 
 
makes them rather unattractive leads for the development of DC-SIGN antagonists, at 
least in their monovalent form. 
 
1.10.2 Mannose-based DC-SIGN antagonists 
Mannose-based DC-SIGN antagonists have been studied extensively and have attracted 
more attention that fucose-based ones. This observation could be attributed to the simple 
fact that the majority of native DC-SIGN ligands either contain mannose or are highly 
mannosylated.  
Mitchell et al. have reported 2-C-substituted branched D-mannose analogues 1.5a-1.5d 
that bind DC-SIGN with an affinity up to an order of magnitude greater than that for D-
mannose[24]. In particular, they found that 2-C-aminomethyl-D-mannose 1.5c exhibits a 
48-fold stronger binding to DC-SIGN, as determined using a surface plasmon resonance 
(SPR)-based competition assay that measures inhibition of DC-SIGN-HIV gp120 
binding. For comparison only, the undecasaccharide Man9GlcNAc2, showed only modest 
affinity in the same assay. This confirms that monsaccharide unit, if substituted properly 
to allow for additional interactions, may be used as a lead compound. 
                                                                                                       
 
 
 
 
(Mitchell et al. (2007) Tetrahedron: Asymmetry[24]) 
Fig. 1.11: Monovalent mannose-based DC-SIGN antagonists. 
 
Based on this observations, Reina et al. have reported the pseudo-1,2-mannobiosides 
1.7a-1.7c as metabolically stable DC-SIGN antagonists. These compounds were designed 
as mimics of the Manα1-2Man 1.6, presents in all Man9 terminal arms and involved in 
high mannose recognition process by DC-SIGN receptor. Indeed, it has been 
demonstrated that high-density arrays of unbranched Manα1-2Man-terminated 
oligosaccharides bind to DC-SIGN almost as efficiently as the entire Man9
[21]. This 
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suggests an important role of nonreducing Manα1-2Man fragment of Man9 in DC-SIGN 
recognition. The three DC-SIGN antagonists 1.7a-1.7c contain a D-mannose unit 
substituted at the anomeric position with conformationally constrained cyclohexanediol, 
which acts as a mimic of the reducing end mannose ring, and features a space-arm 
terminated with methy 1.7a, ethylazido 1.7b, or ethylamino 1.7c functionality, useful for 
generating multivalent DC-SIGN ligands[25]. 
 The inhibitory activity of 1.7c was tested using an infection model based on Ebola virus 
entry into DC-SIGN expressing Jurkat cells and the IC50 measured was approximately 
three times lower than that for the natural disaccharide 1.6. This biological data showed 
that the pseudodisaccharide 1.7c is a stronger inhibitor than the corresponding 
disaccharide 1.6 and taking into account its enzymatic stability could be considered as a 
promising candidate to prepare multivalent system to be used as inhibitors of viral 
infection.  
 
 
 
 
 
(Reina et al. (2007) ChemMedChem[25]) 
Fig. 1.12: Mannose-based DC-SIGN antagonists with their IC50. 
 
Using the same strategy, Mari et al. have designed a pseudo-trisaccharide 1.9 as a mimic 
of the linear trimannoside Manα1-2Manα1-6Manα 1.8, a terminal trimannoside branch 
of Man9, by replacing the central mannose unit with a carbocyclic diol previously 
reported[26]. Using an SPR-based competition assay that measures inhibition of DC-
SIGN-mannosylated BSA binding, the same group determined the IC50 values for 
mannose (1.8 mM), pseudo-dimannoside 1.7b (1.0 mM) and 1.9 (125 µM)[27]. These 
results showed that the addition of a second mannose unit mimicking an α1-6 link and 
resulting in a linear trimannoside mimic improves the affinity by 1 order of magnitude 
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relative to mannose, thus confirming a direct contribute of the additional carbocyclic-diol 
in the binding to DC-SIGN CRD. Considering the highest affinity of the trimannoside 
mimic 1.9, the latter has been selected for attachment to tetravalent dendrons. 
 
 
 
 
 
 
 
(Sattin et al. (2010) ACS Chem. Biol.[27]) 
Scheme 1.1: Linear trimannoside Manα1-2Manα1-6Manα 1.8 and its mimic 1.9. 
 
The most potent monovalent DC-SIGN antagonists reported to data are the mannose-
based glycomimetics of Obermajer et al[28]. They identified two areas around Phe313 in 
the DC-SIGN binding site (PDB code 1SL4) that were only partially occupied by co-
crystallized tetramannoside Man4. Thus, they proposed that these areas could be used to 
increase the potency of glycomimetic DC-SIGN antagonist. 
 Starting with this hypothesis, they used the pseudo-1,2-mannobioside 1.7b[25] to attach 
different hydrophobic moieties to deprotected carboxylates of 1.7b. This resulted in a 
small, focused library of mannose-based DC-SIGN antagonists, whose activity was 
evaluated using a DC adhesion assay to mannan-coated plates[29]. The majority of 
synthesized compounds inhibit DC adhesion at low micromolar concentrations, which 
makes them more potent than the starting compound 1.7b by up to two orders of 
magnitude.  
The results of biological assays indicate that the compounds make additional interactions 
with DC-SIGN CRD, and further docking studies suggested that the attached hydrophobic 
moieties could occupy one or both the predicted additional binding sites.  
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(Obermajer et al. (2011) Mol. Divers.[28]) 
Scheme 1.2: Design of mannose-based DC-SIGN antagonist reported by Obermajer et al., and the most 
potent compounds 1.10a-1.10c. 
 
With these goals in mind, Bernardi et al. synthesized a group of functionalized bis-
benzylamides of general formula 1.11. They contain an azidoethanol linker, which can be 
exploited for conjugation, and different polar groups on the benzylamide ring, to increase 
water solubility and possibly improve affinity for the receptor[30].  
Many of the diamides prepared showed a remarkable increase in inhibitory activity 
compared to diester 1.7b and some approached the affinity observed for 1.9, a molecule 
of significantly higher structural and synthetic complexity. In this library the compound 
1.11a was selected as an optimal ligand for the future construction of multivalent system, 
considering the inhibitory activity and the solubility.  
To analyze the effect of the stereochemistry of cyclohexane scaffold, the same group 
synthesized compound 1.11b, a diastereoisomer of 1.11a with the opposite configuration 
(1R,2R) of the cyclohexane ring[30]. This compound binds poorly to DC-SIGN, which 
indicates that the design of the pseudodisaccharide scaffold is important to optimize 
interaction with the protein.    
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(Bernardi et al. (2013) Chem. Eur. J.[30]) 
Fig. 1.13: Library of bis-benzylamides synthesized by Bernardi group. 
 
 In conclusion it was showed that the development of DC-SIGN antagonists with a 
mannose anchor is good strategy thanks to the high affinity of the mannose for the DC-
SIGN CRD. However, the major problem of mannose-based DC-SIGN antagonists 
respect to fucose-based ones, may be their low selectivity against Langerin, since both 
receptors recognize high-mannose type saccharides. Indeed, both receptors bind glycan 
ligands with structurally very similar Ca2+ dependent CRDs. Interestingly Langerin CRD 
possesses 2 glycan binding sites, one of which is Ca2+ independent, and even the one with 
high structural similarity to DC-SIGN CRD has a different binding site topology.  
To compare the binding selectivity of DC-SIGN against Langerin, Holla et al. screened 
275 synthetic carbohydrate compounds against bacterially produced monomeric CRDs of 
both DC-SIGN and Langerin[31]. They found that DC-SIGN binds preferentially internal 
residues of high-mannose type saccharides, while Langerin preferred saccharides with 
terminal mannose. In particular, the disaccharide Manα1-2Man showed 4-fold higher 
selectivity for DC-SIGN than Langerin. This study showed unequivocally that DC-SIGN 
and Langerin may be independently targeted with mannose-based compounds.     
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1.10.3 Shikimic acid-based DC-SIGN antagonists  
Recently, Garber et al. reported a solid-phase synthetic approach to synthesizing 192 
compounds with the general formula 1.12[32]. The compounds were designed based on 
the observation that shikimic acid shares the same placement of hydroxyls at position 2,3 
and 4 and could therefore replace the mannose unit in interaction with Ca2+ in the DC-
SIGN CRD. The compounds were screened using a fluorescence-based, high-throughput 
competition assay that assesses the ability of compounds to compete with immobilized 
mannan for binding to fluorophore labelled DC-SIGN extracellular domain. The 
compound 1.12a had the highest affinity to DC-SIGN, in this assay, with an IC50 of 3.2 
mM. 
 
 
 
 
 
 
 
 
 
(Garber et al. (2010) Chem. Commun.) 
Scheme 1.3: Strategy of shikimic acid-based design of DC-SIGN antagonists and the most potent hit 
1.12a. 
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1.11 Multimeric presentation  
DC-SIGN native ligands, such as HIV gp120, are highly glycosylated and exploit the 
multivalent presentation of monosaccharides in order to increase binding affinity and 
avidity. Monovalent ligands, even the most potent ones, can barely exceed the binding 
avidity of polyvalent ligands, where one large molecule interacts with 4 CRDs of DC-
SIGN tetramer or even clusters of tetramers. This is of paramount importance when 
designing potent DC-SIGN antagonists, as the problem of binding avidity can be 
overcome only by multiple loading of monomeric unit onto polymeric support.  
Dendrimers, macromolecules with defined globular shape and polyvalent presentation, 
could be the ideal choice for loading multiple copies of monovalent ligands[33]. One of 
first examples of such an approach is the inhibition of viral adhesion using sialic acid-
conjugated dendritic polymers[34]. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.14: Strategy for design high-affinity polyvalent DC-SIGN antagonists. 
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The first evidence that pathogen-DC-SIGN interaction might be successfully inhibited by 
a glycodendritic structure came from the laboratories of Rojo and Delgado[35]. They 
designed and synthesized a simple glycodendritic structure bearing 32 mannose residues 
conjugated to BoltornH30 dendrimer through a succinic acid spacer 1.13. The latter was 
proven to block DC-SIGN mediated Ebola virus infection at nanomolar concentrations 
(IC50 = 337 nM), while the same inhibition was archived only with millimolar 
concentrations of α-methyl-D-mannopyranoside (IC50 = 1.23 mM). Thus, it is clear that 
dendrimeric presentation brings avidity to the interaction. The same group has 
synthesized BH20sucMan 1.14 with 20 presentations of mannose unit[36]. Both 1.13 and 
1.14 were shown to inhibit HIV gp120-DC-SIGN interaction (as measured with SPR) and 
strong inhibition was observed for 1.13 only, showing the major impact of mannose 
density and dendrimer size on interaction with DC-SIGN. Conjugation of 1.7c to a 
Boltorn-type dendrimer through a succinic acid linker yielded the polyvalent ligands 1.15, 
bearing an average number of 26 units of pseudo-disaccharide 1.7c. In preliminary 
experiments, this molecule inhibited binding of DC-SIGN extracellular domain to a 
gp120-coated SPR six times better than BH30sucMan 1.13[37].   
 
 
Fig. 1.15: Chemical structure of Boltorn H30 dendrimer and Boltorn H20 dendrimer.  
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Fig. 1.16: Glycodendritic structures as DC-SIGN antagonists. 
 
Sattin et al. demonstrated how a potent monovalent DC-SIGN antagonist might reduce 
the requirement for huge dendrimeric presentation while retaining desired effect[27]. 
Using a dendron that bears only four copies of linear trimannoside mimic 1.9 they show 
that HIV-1 transfection to CD4+ T lymphocytes can be successfully blocked (>94% 
inhibition at 100 µM) by inhibiting DC-SIGN gp120 interaction. In contrast, a tetrameric 
dendron bearing 4 copies of simple mannose 1.18 inhibited HIV-1 transfection only 
partially (65% inhibition at 100 µM).  
Tetravalent dendron 1.17 showed an IC50 one order of magnitude lower than dendron 1.19 
bearing 4 copies of 1.7c. Surprisingly, this difference was not observed in multivalent 
system. Dendrimers 1.15 and 1.16, with an average of 30-32 copies of 1.7c and 1.9, were 
almost equipotent in the same assay, with IC50 values of approximately 20 nM, which is 
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one to two orders lower than those of the corresponding tetravalent systems. All the data 
shows that polyvalent presentation is obligatory for obtaining high-affinity DC-SIGN 
antagonists, but the polyvalency itself can be reduced to a degree of tetrameric 
presentation 
 
 
 
 
 
 
 
 
 
 
 
 
(Sattin et al. (2010) ACS Chem. Biol.[27]) 
Fig. 1.17: Dendron-based DC-SIGN antagonists of Saattin et al.  
 
Garber et al. loaded monovalent glycomimetic 1.12a onto a multivalent scaffold by ring-
opening metathesis polymerization (ROMP, Fig. 1.18)[32]. This ROMP-derived 
glycopolymers was designed to link at least 2 CRDs of DC-SIGN tetramer, and the final 
glycopolymer bears 29 copies of 1.12a. The IC50 value of this glycopolymer was found 
to be 2.9 µM, which is 1000-fold lower than that of monomer 1.12a. 
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(Garber et al. (2010) Chem. Commun.[32]) 
Fig. 1.18: Glycopolymers of Garber et al. 
 
In conclusion, the tactics of polyvalent presentation described might be used as a general 
strategy when designing antagonists of C-type lectins, where binding of native 
polysaccharides has to be antagonized. 
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1.12 Non-carbohydrate DC-SIGN antagonists obtained by 
screening compound libraries 
In contrast to the numerous DC-SIGN antagonists obtained by traditional glycomimetic 
approaches, one high-throughput screening campaign was performed with the aim to 
obtain non-saccharide DC-SIGN antagonists. Borrok and Kiessling screened two 
commercially available, small molecule libraries of together 36.000 compounds[39]. Using 
a high-throughput screening optimized screening method with immobilized DC-SIGN 
they identified 7 compounds (1.20-1.26) with IC50 values in the low micromolar range.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Borrok and Kiessling (2007) J. Am. Chem. Soc.[39]) 
Fig. 1.19: Structure of non-saccharide small molecule DC-SIGN antagonists and their IC50. 
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The highlight of these hits is that neither of them is similar to native mono- or 
oligosaccharide ligands as they display no saccharide units or their mimics at all. The lack 
of carbohydrate or carbohydrate-like structures clearly indicates that carbohydrate 
features are not indispensable for effective DC-SIGN antagonism.  However, as these 
molecules lack functional groups that could chelate Ca2+ effectively, one can only 
speculate on their binding mode; instead of a competitive binding into a carbohydrate 
binding site, these compounds may occupy an extended binding site, or even an allosteric 
binding site.  
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2. RESULTS AND DISCUSSION 
 
2.1 State of art 
The development of DC-SIGN antagonists is of paramount importance to block the sugar 
binding site within DC-SIGN CRD to prevent its use by pathogens’s glycoproteins, like 
HIV gp120. DC-SIGN/pathogen interactions are complex and imply multipoint 
attachment benefiting from the DC-SIGN tetrameric state and from its organization into 
clusters. For this reason, almost all of inhibition strategies exploit a multiple ligand 
presentation platform, on which the relevant ligands are presented for interaction with 
DC-SIGN CRD. As seen in the previous section, dendrimers loaded with multiple copies 
of mannose were able to inhibit DC-SIGN/gp120 interaction. However, mannose, as 
natural ligand, is not specific enough for in vivo practical applications. Thus the design 
of a ligand with good selectivity and basal affinity becomes of crucial importance. Several 
groups have invested efforts in DC-SIGN ligand improvements by increasing the 
complexity of the oligosaccharide (reconstructing natural high mannose oligosaccharide, 
for instance), by selecting nonsugar molecules with high throughput screening or by 
designing new synthetic molecules mimicking natural sugar properties. On the basis of 
the natural ligand Manα1-2Man 1.6, a terminal disaccharide presents in all Man9 arms, 
Professor Anna Bernardi’s group reported some of the most interesting antagonist 
compounds with general formula 1.7 and with good affinity for DC-SIGN and low 
structural complexity[25].   
 
 
 
 
 
 
Fig. 2.1: Manα1-2Man and the Bernardi’s mimic 1.7a-1.7c. 
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 In a recent paper was determined for the first time the high-resolution structure of a 
glycomimetic 1.7c/DC-SIGN complex by x-ray crystallography comparing it with that of 
Manα1-2Man[40]. It has been shown that the natural ligand Manα1-2Man disaccharide 
displays at least two different binding modes within the Ca2+ binding site: the major mode 
is achieved by coordination to the Ca2+ ion of the 3-OH and 4-OH equatorial groups of 
the reducing end mannose residue (Fig. 2.2a), while the minor one occurs through the 
same groups of the nonreducing end mannose ring (Fig. 2.2b). The pseudo-1,2 
mannobioside 1.7c, contains a single mannose unit at the nonreducing end, and could be 
expected to bind DC-SIGN similarly to the minor binding mode of Manα1-2Man, which 
involves the nonreducing end mannose and would possibly generate a favorable 
interaction between Phe313 of the secondary binding site and the cyclohexane moiety of 
1.7c. Surprisingly, 1.7c was found to interact through a third distinct mode: the position 
of Ca-binding diol (mannose 3-OH and 4-OH) is swapped relative to Manα1-2Man 
complex, so that the 3-OH group of 1.7c contacts E354 (as opposed to the 4-OH group of 
Manα1-2Man) and that the 4-OH group of 1.7c contacts E347 (as opposed to the 3-OH 
group of Manα1-2Man), while the cyclohexane ring participates in the interaction through 
van der Waals contacts with V351[40] (Fig. 2.2c). 
 
Fig. 2.2: Comparison of pseudo-1,2-mannobioside 1.7c and Manα1-2Man binding modes.  
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Thus, 1.7c and Manα1-2Man have totally different DC-SIGN binding modes. On the 
contrary, strong similarity is observed with the binding epitope of Lewis X derivatives, 
which also exploits van der Waals contacts with V351. These results therefore suggest 
that addition of lipophilic groups to the cyclohexane scaffold of 1.7c should allow one to 
extended contacts with the protein surface, which might improve the affinity and the DC-
SIGN specificity to higher level.  
Within a collaboration with Bernardi’s group[25], in the laboratory where I carried out my 
thesis were synthesized two new pseudo-disaccharides (+)-2.1a  and (-)-2.1b, as a real 
mimic of the natural DC-SIGN ligand Manα1-2Man. The glycomimetics (+)-2.1a and (-
)-2.1b are conceptually analogues to the compound 1.7c, but compared to the latter they 
have more structural similarity with Manα1-2Man. Indeed, in the glycomimetics (+)-2.1a 
and (-)-2.1b was introduced a real D-carbamannose core as mimic of the reducing 
mannose moiety, presents instead in the Manα1-2Man, while a mannose anchor forms 
the nonreducing unit (as in the Manα1-2Man) and allows to interact with the Ca2+ ion 
within DC-SIGN CRD. The ethilamino (+)-2.1a and ethilazido (-)-2.1b chains are useful 
for a multimeric presentation onto dendrimers increasing the affinity with the receptor, 
exploiting the tetramerization of DC-SIGN and their subsequently organization into 
clusters.    
 
 
 
 
 
 
Fig. 2.3: The two pseudo-1,2-mannobiosides (+)-2.1a and (-)-2.1b synthesized in our laboratory.  
 
The two pseudo-disaccharides were obtained by a simple glycosylation between a 
carbamannose unit 2.2, as glycosyl acceptor, and the mannose trichloroacetimidate unit 
(-)-2.3, as glycosyl donor, (Scheme 2.1). 
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Scheme 2.1: Glycosylation between the glycosyl-acceptor 2.2 and the glycosyl-donor (-)-2.3 to obtain the 
pseudo-1,2-mannobioside with general formula 2.1. 
 
The principal difference between the two pseudo-disaccharides (+)-2.1a and (-)-2.1b is 
the terminal group onto the side chain, thus changing the R' group on the carbamannose 
unit 2.2 we obtain both the compounds. Interestingly, the two pseudo-disaccharides 
derive from the same key intermediate, the 6-O-benzy-1,2-anhydro-5a-carba-β-D-
mannopyranose (+)-2.6. Two different elaborations of this latter allow obtaining the tri-
O-benzyl- β-epoxide (+)-2.4β and the tri-O-acetyl- β-epoxide (+)-2.5 β, each of which 
through different synthetic steps led us to the corresponding final compounds (+)-2.1a 
and (-)-2.1b (Scheme 2.2).       
 
 
 
 
 
 
 
 
 
 
Scheme 2.2: Key intermediate (+)-2.6 in the synthesis of pseudomannobiosides (+)-2.1a and (-)-2.1b. 
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The synthesis of the key intermediate (+)-2.6 begins by a commercially available tri-O-
Acetyl-D-glucal (+)-2.7, which was converted into the primary alcohol (-)-2.8 and 
subsequently switched into the corresponding carba analogue (-)-2.9, in which a 
methylene group replaces the endocyclic oxygen. Then, the residual double bond present 
in (-)-2.9 was subjected to a stereoselective epoxidation to afford the pivotal epoxy diol 
(+)-2.6. 
 
 
 
Scheme 2.3: Principal steps in the synthesis of the key intermediate (+)-2.6. 
 
From the Key intermediate (+)-2.6 was selectively obtained only the pseudo-disaccharide 
(+)-2.1a, through benzylation of the free hydroxyl groups of (+)-2.6, and with a 
subsequent ring-opening reaction by an appropriate nucleophilic agent, the azido-ethanol.  
 
 
 
 
 
 
Scheme 2.4: Synthesis of the azido-ethoxy-glycosyl acceptor (+)-2.2a. 
 
In this way, was we obtained the glycosyl acceptor (+)-2.2a, ready for the glycosylation 
step with the appropriate mannosyl donor, the trichloroacetimidate (TCA) (-)-2.3 
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protected as benzoyl derivate, as previously seen. The glycoconjugate (-)-2.10 obtained 
in a completely α-stereoselective fashion and with a yield of 85% was debenzylated under 
reducing conditions (catalytic hydrogenation H2,Pd/C 10%), to afford (-)-2.11. The next 
removing of the benzoyl groups through saponification (MeONa/MeOH) afforded the 
final pseudo-disaccharide (+)-2.1a in 70% yield.    
 
 
 
 
 
 
 
 
 
 
Scheme 2.5: of 2-aminoethyl-pseudo-1,2-mannobioside (+)-2.1a. 
 
To obtain instead only the pseudo-disaccharide (-)-2.1b, it was followed a different 
synthetic pathway.  
Starting always from the key intermediate (+)-2.6, common to both pseudo-disaccharides, 
through a reducing reaction with H2/Pd-C 10% was obtained the β-epoxy triol (+)-2.12β. 
The latter was acetylated with the aim to protect the free hydroxyl groups as acetyls, 
obtaining the tri-O-acetyl- β-oxirane (+)-2.5β, and subsequently submitted to a ring 
opening reaction with the 2-azido-ethanol as nucleophile, to afford the (2-azidoethyl)-
3,4,6-tri-O-acetyl cyclohexanol derivative (+)-2.2b, as a new glycosyl acceptor. 
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Scheme 2.6: Synthesis of azido-ethoxy-glycosyl acceptor (+)-2.2b.   
 
This new intermediate (+)-2.2b was subjected to glycosylation with the usual TCA 
derivate (-)-2.3 as glycosyl donor to afford the fully-O-protected pseudomannobioside (-
)-2.13, who was totally deprotected by a simple saponification obtaining the fully-O-
deprotected pseudo-disaccharide (-)-2.1b in good yield (88%).     
 
 
 
 
 
 
 
 
 
Scheme 2.7: Synthesis of 2-azidoethyl-pseudo-1,2-mannobioside (-)-2.1b. 
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The inhibitory activity of the two synthesized pseudo-disaccharides (+)-2.1a and (-)-2.1b 
was tested by the professor Frank Fieschi's group at Institut de Biologie Structurale-Jean-
Pierre Ebel, in Grenoble (France). The assays carried out, expect the use of an infection 
model based on Ebola envelope-pseudotyped viruses and Jurkat cells expressing DC-
SIGN[25]. This infection model was previously used for testing the inhibitory activity of 
the compound 1.7c, therefore, the results of the biological assays were here reported for 
the compounds (+)-2.1a and (-)-2.1b compared with those of the natural ligand Manα1-
2Man and those of compound 1.7c. The results were expressed using the IC50 values of 
each compounds in µM range. As we can see, these IC50 values for the two pseudo-
disaccharides (+)-2.1a and (-)-2.1b are 
very similar to each other and slightly 
higher than those of the natural ligand 
Manα1-2Man and 1.7c. The results thus 
obtained demonstrated a good affinity 
for the compounds (+)-2.1a and (-)-2.1b 
to DC-SIGN CRD, although slightly 
lower to that of Manα1-2Man. However, 
taking into account their enzymatic 
stability, (+)-2.1a and (-)-2.1b could be 
considered as a possible lead compounds 
for the future synthesis of new DC-SIGN 
antagonists through simple changes.    
 
Fig. 2.4: IC50 values for the compounds (+)-2.1a 
(an99), (-)-2.1b (LC861), the ester analog 1.7c (psdi) 
and Manα1-2Man. 
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2.2 Purposes of the thesis  
On the basis of previous observations and with the acquired experience through the 
precedent synthesis of the two DC-SIGN antagonists (+)-2.1a and (-)-2.1b, in the group 
where I carried out my thesis was decided to continue the investigation about DC-SIGN 
field in order to develop a new antagonist with less polar characteristics and a possible 
better inhibitory activity. Thus the main purpose of this thesis is the stereoselective 
synthesis of a new pseudo-1,2-mannobiose (+)-2.14, mimic of the natural ligand Manα1-
2Man, as a DC-SIGN antagonist. The principal structural hallmarks of this pseudo-1,2-
mannobioside are: 
 A nonreducing unit composed by a mannose moiety. 
 A reducing unit composed by a D-carbamannose moiety with a methyl group at 
the C(5) position, essential for the introduction of a lipophilic portion. 
 A terminal ethylamino tail.   
 
 
 
 
 
 
 
Fig. 2.5: Pseudo-1,2-mannobioside (+)-2.14 and its structural hallmarks. 
  
The mannose moiety is essential to interact with the DC-SIGN receptor, indeed it allows 
to establish coordination bonds with the Ca2+ ion within the DC-SIGN CRD. In particular, 
the equatorial 3- and 4- hydroxyls of the mannose moiety are directly involved in the 
formation of these contacts together with the axial 2-hydroxyl group. The carbamannose 
moiety was introduced as mimic of the reducing mannose unit present instead in the 
natural ligand Manα1-2Man, its function is to interact with the DC-SIGN binding site 
establishing secondary interactions (like the reducing mannose unit in the Manα1-2Man), 
increasing the affinity to the receptor, and at the same time giving more enzymatic 
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stability to the antagonist. Particularly the mimic function of this moiety is attributable to 
the substitution of an oxygen atom with a methylene group which leading us to obtain a 
cyclohexane ring with the same stereochemistry of the D-mannose unit. The terminal 
ethylamino tail is useful for the obtaining of a nonreducing pseudo-disaccharide and 
moreover for a possible conjugation of the compound (+)-2.14 onto dendrimers in order 
to increase the inhibitory activity. This new pseudo-1,2-mannobioside (+)-2.14 was 
designed starting from the previous synthesized antagonist (+)-2.1a by a simple change 
in the D-carbamannose moiety. The hydroxymethyl group present in the C(5) position of 
the reducing unit into the pseudo- mannobioside (+)-2.1a was substituted with a methyl 
group in our antagonist (+)-2.14.   
 
 
 
 
 
 
Scheme 2.8: Introduction of the methyl group in the C(5) position of the carbamannose moiety. 
 
The methyl group has the aim to increase the lipophilicity of the cyclohexane ring in order 
to enhance the affinity to the receptor. Indeed, this moiety interacts with the DC-SIGN 
receptor mainly through van der Waals interactions, and as previously seen (state of 
art[40]), the increasing in the lipophilicity of the carba core enhances these interactions. 
Thus, based on these observations we thought to replace a polar group as the 
hydroxymethyl group at the C(5) position with a less polar and, at the same time, less 
bulky group as the methyl group in order to achieve this target. The synthesis of the 
glycomimetic (+)-2.14 proceed through a synthetic pathway different from those used for 
the synthesis of the two pseudo-1,2-mannobiosides (+)-2.1a and (-)-2.1b. However, the 
final steps allow the obtaining of (+)-2.14 by a simple glycosylation reaction followed by 
hydrogenation and saponification, exactly as for the synthesis of (+)-2.1a. Therefore, the 
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obtaining of the glycosyl-acceptor (+)-2.15 represents the key step as well as the real 
difference in this synthetic pathway. 
 
2.2.1 Synthesis of the glycosyl-acceptor (+)-2.15 
For the synthesis of the glycosyl-acceptor (+)-2.15 we selected to use carbohydrates as 
starting material. This choice brings a key advantage in our synthetic pathway, indeed the 
enantiomeric purity of the target carbasugar is guaranteed by the enantiomeric purity of 
the starting material. The use of a chiral starting material besides allows us to avoid the 
obtaining of complex reaction mixture of diasterisomeric compounds providing thus a 
reproducible synthetic strategy. The chiral carbohydrate selected for begin our synthesis 
is the commercially available tri-O-acetyl-D-glucal (+)-2.7. This compound owns the 
same stereochemistry in the C(3), C(4) and C(5) positions needed for the target glycosyl-
acceptor (+)-2.15, and regarded its cheapness and easy availability, it represents the ideal 
starting material. 
 
 
 
 
 
 
 
 
 
Scheme 2.9: Synthesis of primary alcohol 2.19. 
 
The first goal in our synthetic pathway is the obtaining of the primary alcohol 2.19, 
starting point for the synthesis of the glycosyl-acceptor (+)-2.15. Thus the tri-O-acetyl-
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D-glucal ((+)-2.7) was saponified in MeONa/MeOH with the purpose to remove the 
acetyl groups to provide the fully deprotected D-glucal (+)-2.16. The latter was then 
subjected to a selective silylation on the primary hydroxyl group with a tertiary butyl 
dimethyl silyl chloride (TBDMSi-Cl) in presence of imidazole as catalyst and a mixture 
of DMF and THF as solvent, to afford the trans diol 2.17.  
The subsequent protection of the free hydroxyls of the trans diol 2.17 represents a crucial 
step due to the protecting group utilized, which must be able to resist in the reaction 
conditions used in the next synthetic steps. The protecting group thus utilized for this 
purpose was the benzyl group, whereby the trans diol 2.17 was benzylated on the C(3) 
and C(4) hydroxyls with benzyl bromide, in presence of a base like sodium hydride 
(NaH), tetrabutylammonium iodide (TBAI) as catalyst and THF as solvent, obtaining the 
fully protected D-glucal 2.18.  
The last reaction in this first stage of our synthetic pathway is the obtaining of the primary 
alcohol 2.19 through a desilylation of the hydroxyl in the C(6) position of the fully 
protected D-glucal 2.18. This reaction initially was conducted at 0°C with the addition of 
the tetrabutylammonium fluoride (TBAF) in THF as solvent, subsequently in our 
laboratory was developed a different procedure which expected only the addition of the 
TBAF at 0°C while the reaction is conducted at room temperature, increasing in this way 
the yield (80% after flash chromatography) and reducing the reaction times.  
As previously anticipated the primary alcohol 2.19 is just the starting material required 
for the conversion of the D-glucal in our target carbasugar 2.23, in particular to realize 
this purpose we decided to use an application of the Claisen thermal rearrangement, 
described by Nagarajan and Sudha[41] in 1998 and already in use in our laboratory in the 
past few years[42]. 
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Scheme 2.10: Synthesis of carba alcohol 2.23. 
 
This consolidated protocol allows to obtain the carbacyclic 2.23 through a few simple 
reactions, in particular an oxidation to aldehyde 2.20 followed by a Wittig reaction to 
obtain an olefin (-)-2.21, which was submitted to a Claisen rearrangement and subsequent 
reduction to afford the carbasugar 2.23. The latter through a simple elaboration leads to 
the final glycosyl-acceptor (+)-2.15.  
The first step in this second stage of our synthetic pathway, as seen above, is the selective 
oxidation of the primary alcohol 2.19 to aldehyde using as oxidizing agent a freshly 
prepared 2-iodoxy benzoic acid (IBX). The IBX was chosen because is a mild and 
versatile oxidant, active against alcohols and vicinal diols, maintaining unchanged the 
double bounds. Besides, IBX is well known as oxidizing agent also because is the 
precursor for the synthesis of Dess-Martin reagent (DMP), more soluble in organic 
solvents (Scheme 2.11).  
In the past the synthesis of the IBX was very complex but in the 1999 was developed by 
Frigerio et all. a new synthetic procedure more easy and clean for the obtaining of the 
IBX in a good yield (80%) and with highly purity degree (≥95%)[43]. 
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Scheme 2.11: Synthesis of IBX, and DMP. 
 
This procedure was utilized in our laboratory for preparing the IBX required for the 
oxidation step, and expected the oxidation in water of the 2-iodobenzoic acid with a 
commercial Oxone® (2KHSO5-KHSO4-K2SO4) for 3h at 70°C. Once synthesized, the 
freshly IBX can be utilized for the oxidation of the compound 2.19 in an appropriate 
solvent in which it results soluble, in our case ethyl acetate at 70-80°C. As a result of the 
oxidation reaction was obtained the desiderate aldehyde 2.20 with a high level of purity, 
which enables to use it directly in the next step without any purifications. However, the 
aldehyde 2.20 is quite unstable, reason why must be subjected quickly to the next reaction, 
anyway there is also the possibility to conserve it for 36h at -78°C under dry ice.  
The subsequent reaction to which the aldehyde 2.20 was directly subjected is the Wittig 
reaction, which allows to convert the aldehyde portion into a double bond. This reaction 
proceed through the adding of an appropriate base as the KHMDS at a solution of our 
aldehyde 2.20 in THF together with the triphenylphosphine methyl iodide (PPh3CH3I). 
Initially as a base was utilized a solution of KHMDS in THF 0,5 M but subsequently we 
decided to replace it with a solution of LHMDS in THF 0,1 M reducing in this way the 
volume of the reagent required, and at the same time keeping unchanged the final yield. 
 After Wittig reaction we obtained the glycal-derived-6-exocyclic olefin (-)-2.21 together 
with the triphenylphosphine oxide (PH3PO) as subproduct, thus it is necessary to remove 
this latter in order to obtain only the desired clean olefin (-)-2.21. In our laboratory was 
developed an easy work-up which allows to remove the triphenylphosphine oxide 
(PH3PO) obtaining the clean olefin (-)-2.21 ready for the next reaction, without the use 
of any purification technique. This procedure is composed by three steps: a first filtration 
on Celite® pad followed by a washing of the organic phase with various aqueous solutions 
and finally by a second filtration on silica gel-Fluorosil® pad. The subsequent evaporation 
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of the organic phase afforded the olefin (-)-2.21 in good yield (68%) without any residual 
of PH3PO and ready for the Claisen rearrangement. 
The Claisen rearrangement is a [3,3] sigmatropic rearrangement in which a vinyl allyl 
ether is thermally converted into a γ,δ-unsaturated carbonyl compound. 
 
 
Fig. 2.6: [3,3] sigmatropic rearrangement. 
 
In our case the glycal-derived-6-exocyclic olefin (-)-2.21 represents a peculiar substrate, 
indeed it owns two double bonds, one exocyclic and the other endocyclic and both are 
part of the vinyl allyl system. Thus subjecting this substrate to a Claisen thermal 
rearrangement the vinyl allyl ether system seen above is converted into the corresponding 
γ,δ-unsaturated carbonyl system forming the carba-aldehyde 2.22, through a mechanism 
depicted in the Scheme 2.12. 
 
 
 
 
 
Scheme 2.12: Claisen thermal rearrangement of glycal (-)-2.21. 
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The Claisen rearrangement represents the heart in our synthetic strategy precisely because 
it allows to convert a glycal structure as (-)-2.21 into a carbcyclic ones as 2.22, allowing 
thus, to begin our synthetic pathway by a chiral carbohydrate compound. Besides, the 
Claisen rearrangement enables the obtainment of high optical purity products from chiral 
and enantiomerically enriched starting material, like in our case.  
The rearrangement was carried out following a typical protocol developed in our 
laboratory, a solution of the olefin (-)-2.21 in 1,3 dichlorobenzene was warmed at 240°C 
in a sealed tube for about 1h. For reach the required temperature and keep it steady for all 
the time was utilized a silicone oil (AP 100) stable and not flammable at high 
temperatures, perfectly suitable for this purpose.  
The carba-aldehyde 2.22 thus obtained is unstable, and for this reason was directly 
reduced. Indeed, the Claisen rearrangement and the reduction are two steps of a one-pot 
reaction. Particularly the reaction mixture deriving from the rearrangement was diluted 
with THF and ethanol and subsequently was added the sodium borohydride (NaBH4) with 
the aim to reduce the aldehyde portion to an hydroxymethyl portion. The one-pot reaction 
was followed by a purification through flash chromatography to obtain a final carba-
alcohol 2.23 in good yield (60%).  
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2.2.2 Processing of the carba-alcohol 2.23 
Once obtained the carba-alcohol 2.23, this latter must be subjected to a series of changes 
with the purpose to get the final glycosyl-acceptor (+)-2.15. 
 
 
 
 
Scheme 2.13: Introduction of methyl group on the C(5) position of  the carbancycle to obtain (+)-2.25. 
 
In particular the first change on this core is the introduction of the methyl group in the 
C(5) position through tosylation of the free hydroxyl with subsequent reduction. The 
tosylation was carried out through the adding of tosyl chloride (TsCl) to a solution of the 
carba-alcohol 2.23 in pyridine at 0°C, after that the temperature was increased at room 
temperature. The crude of the reaction was directly evaporated, to afford the compound 
(-)-2.24, together with the pyridinium salts. Finally, the crude was subjected to a flash 
chromatography with a mixture 8:2 dichloromethane/hexane with the aim to solubilize 
the pyridinium salts, soluble in CH2Cl2, and purify the fully protected carbacycle (-)-2.24 
(85% yield). We preferred to follow this procedure instead of treat the reaction with acid 
aqueous solution to avoid the partially degradation of the product. 
The carba-alcohol 2.23 was tosylated with the purpose to introduce a good leaving group 
on the free hydroxyl, in this way the tosylate ester obtained can be easily reduced to a 
methyl group. Consequently, the fully protected unsaturated carbacycle (-)-2.24 was 
solubilized in diethyl ether (Et2O) and subsequently was added the lithium aluminum 
hydride (LiAlH4) at the temperature of 0°C to afford the methyl-carbacycle (+)-2.25. This 
latter was obtained with a good degree of purity and so can be directly subjected to the 
follow changes.      
The next step is the epoxidation of the methyl-carbacycle's double bond to obtain the β-
epoxide (+)-2.26β, which then is submitted to an opening reaction with an adequate 
nucleophile as the azidoethanol to afford the final glycosyl-acceptor with the correct 
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stereochemistry. During the epoxidation reaction, the stereoselective obtaining of the β-
epoxide (+)-2.26β was one of the most important problems faced. As reported in literature 
the epoxidation of the triol 2.27[44] and the tri-O-benzyl derivate 2.28[45] is carried out by 
means the meta-chloroperoxybenzoic acid (MCPBA). The described protocol indicates 
that, in these conditions, the tri-O-benzyl olefin leads to a mixture 80:20 of the 
diastereoisomeric epoxides 2.4α and (+)-2.4β, while the triol 2.27, in the same conditions, 
gives a mixture of the corresponding unprotected epoxides 2.12α and (+)-2.12β with an 
inverted ratio 12:88 (Scheme 2.14).  
The explanation of this partial stereoselectivity can be attributed to two distinct factors: 
the steric and the coordination effects. In the tri-O-benzyl derivative 2.28 prevails the 
steric effect attributable to the benzyl groups, indeed these latter are bulky groups and 
thus they direct the periacid approach on the opposite α-face, leading to a prevalent 
amount of the α-epoxide 2.4α. Whereas in the unprotected triol 2.27 the coordination 
effect is the prevalent one due to the absence of the bulky protecting groups. Whereby the 
peracid is direct on the β-face exploiting the effect of the allyl-hydroxyl group, which is 
able to establish a hydrogen bond with the oxidant (MCPBA). As consequence of this 
bond is obtained a diastereoisomeric excess of the β-epoxide (+)-2.12β. 
 
 
 
 
 
 
 
 
 
Scheme 2.14: Stereoselectivity of the MCPBA epoxidation with the tri-O-benzyl derivative 2.28 and triol 
2.27. 
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In our case the methyl-carbacycle (+)-2.25 presents the allyl-hydroxyl group protected as 
benzyl ether, therefore it cannot establish hydrogen bonds with the peracid, but on the 
contrary the same benzyl group acts as a hindrance which directs the peracid on the α-
face, obtaining thus a diastereoisomeric excess of the α-epoxide. Therefore, the most 
logical choice for increase the amount of β-epoxide obtained is the deprotection of the 
benzyl groups so as to have the allylic hydroxyl free to direct the periacid approach on 
the β-face. However, we have to consider that the deprotection of the benzyl groups 
occurs through catalytic hydrogenation, which also leads to the reduction of the methyl-
carbacycle's double bond, necessary for the same epoxidation. For this reason, we decided 
to proceed equally with the epoxidation of the protected methyl-carbacycle (+)-2.25 by 
means MCPBA, even if in this way is obtained a prevalent amount of the α-epoxide, in 
consideration of the fact that the two diastereoisomers are easily separable and that the 
synthetic pathway is shortened.   
The epoxidation reaction was carried out by the adding of the meta-chloroperoxybenzoic 
acid to a solution of the methyl-carbacycle (+)-2.25 in dichloromethane dry at 0°C, after 
that it was left to room temperature. The obtaining of both diastereoisomers occurs in a 
unique step through the classic butterfly mechanism as illustrated in the next scheme. 
 
 
 
 
 
 
 
Scheme 2.15: Proposed mechanism for the epoxidation of the methyl carbacycle (+)-2.25. 
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After epoxidation was obtained a mixture of the two diastereoisomers, which thus must 
be isolated. This target was achieved by means a flash chromatography with mixture 
Hexane/Ethyl acetate 9:1. This procedure allowed a good separation of the two 
diastereoisomers leading to obtain the pure α- and β-epoxide (+)2.26α and (+)2.26β in 
the ratio 6:4. Therefore, as expected we obtained a prevalent amount of the α-epoxide 
(+)2.26α, but differently from what reported in literature[46] for the tri-O-benzyl derivative 
2.28, in our case the final percentage of β-epoxide was higher than expected (40%).  
With the amount of β-epoxide (+)2.26β recovered we proceed to the opening of the latter 
in order to obtain our glycosyl-acceptor (+)-2.15. As previously anticipated the 
nucleophile used for the opening reaction was the 2-azido-1-ethanol, freshly prepared 
using a particular protocol suggested by Bernardi’s group.  
The method, safe and not hazardous, provided the preparation of a 1.3 M 2-azido-1-
ethanol solution in CH2Cl2 simply based on the azidolysis of 2-chloro-1-ethanol by NaN3 
in H2O at room temperature. In this way, leading the reaction in an inorganic solvent, we 
had avoided the use of dichloromethane as reaction solvent. Indeed, the use of chlorinated 
solvents could result in the formation of explosively-unstable di- and tri- azidomethane. 
Whereas in these procedure, the reaction mixture was stirred at 70°C in H2O for three 
days and then eluted with dichloromethane, which extracts the desired compound from 
the inorganic phase; the obtained solution was conserved at 4°C under molecular sieves 
and without any distillation step. 
The opening of the 1,2-epoxides with β-manno configuration, as the compound (+)2.26β, 
was extensively reported by Ogawa[47]. These systems react with O- and N- nucleophiles 
by exclusive nucleophilic attack at the favoured C(1) oxiran carbon. This preference of 
the nucleophile towards the C(1) oxirane position respect to the C(2) can be easily 
explained considering the sterically and electronically factors. Indeed, C(1) is flanked by 
an electron-rich methylene group, whereas C(2) is flanked by a carbon bearing an 
electron-withdrawing group, so that, from an electronic point of view,  the SN2 reaction 
should be more favourable at C(1). Besides, the group flanking C(1) is smaller than those 
flanking C(2), so attack at C(1) may be favoured also from a steric point of view[48]. 
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Scheme 2.16: Nucleophilic attack to the 1,2-epoxide with β-manno configuration. 
 
The ring opening reaction of the β-epoxide (+)2.26β in addition to a 2-azido-1-ethanol 
needs a Lewis acid as catalyst in order to activate the oxirane ring, making easier the 
opening and thus accelerating the reaction, in our case was utilized copper (II) 
trifluoromethanesulfonate (Cu(OTf)2) as Lewis acid. In these conditions the opening 
afforded the 2-azido-1-ethoxy-cyclohexanol derivative (+)-2.15, through a completely 
region- and stereoselective nucleophilic attack at the oxirane carbon C(1) and without any 
side reaction products, according to the mechanism depicted in the following scheme.   
 
 
   
 
 
 
 
 
Scheme 2.17: Mechanism of the ring-opening reaction under Lewis acid catalytic conditions. 
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The azido derivative (+)-2.15 obtained owns a good purity degree due to the regio- and 
stereoselectivity of the reaction, and for this reason the product was directly subjected to 
the next glycosylation step without any purifications. 
 
2.2.3 Synthesis of the 6-deoxy carba mannobioside (+)-2.14 
The final pseudo-1,2-disaccharide (+)-2.14 was obtained through three easy synthetic 
steps that include: a glycosylation reaction, which allows the conjugation of the glycosyl-
acceptor (+)-2.15, previously synthesized, with an adequate glycosyl-donor to afford the 
fully-O protected pseudo-disaccharide (-)-2.29, and a catalytic hydrogenation followed 
by a saponification with the aim to totally deprotect (-)-2.29, obtaining the final 6-deoxy 
carba mannobioside (+)-2.14. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.18: Synthesis of the final pseudomannobioside (+)-2.14. 
 
The adequate glycosyl-donor for the glycosylation step is the fully-O-benzoyl D-mannose 
trichloroacetimidate (TCA) (-)-2.3, already available in our laboratory. In particular, this 
latter owns a trichloroacetimidate group (CCl3CORNH) on the anomeric hydroxyl, which 
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during the conjugation with the glycosyl-acceptor (+)-2.15 is released, acting as driving 
force of the reaction, while the other hydroxyls of the mannose are protected as benzoyls. 
These protecting groups help in the obtaining of a higher molecular weight product, stable 
and storable, and at the same time they are easy to remove under basic conditions. 
The conjugation between the glycosyl acceptor (+)-2.15 and TCA derivate (-)-2.3 was 
efficiently carried out in dichloromethane with the trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) as catalyst at -20°C for about 20 minutes, using the 
molecular sieves AW300 to provide anhydrous reaction conditions.  
It was necessary carried out the reaction under anhydrous conditions to avoid that any 
residual of water hydrolyze the TCA derivate. Whereby besides the use of molecular 
sieves, to obtain more drastic conditions the reaction was performed in a flame-dried 
Schlenk, under a positive pressure of Argon, and before the beginning of the reaction was 
added a little amount of toluene to the mixture of the glycosyl-acceptor and the glycosyl-
donor with the aim to create an azeotrope with the residual water and thus easily remove 
it. In this conditions was obtained the glycoconjugate (-)-2.29 in a completely α-
stereoselective fashion and with 80% yield after flash chromatography. 
The most interesting advantage of this glycosylation reaction is the possibility to exercise 
a stereochemical control on the anomeric centre, in order to obtain the α-glycoconjugate 
(-)-2.29 as the only reaction product with a good yield. This stereocontrol is closely 
related to the structure of the glycosyl-donor and especially to the Anomeric effect and 
Anchimeric assistance (or Neighbouring group participation) exercised on this latter. The 
anomeric effect is due to the presence of an heteroatom (bearing lowne pairs) in α to the 
C(1), which thus orients its electronegative group in axial position. The preference of the 
electronegative group on the C(1) for the axial position respect to the equatorial one 
(favored for steric reasons) can be explained considering the hyperconjugation effects and 
the dipoles minimization. Indeed, in the axial position the electric dipoles of the two 
involved heteroatoms are opposed each other, which represents a state at lowest energy 
and so more stable. Moreover, in the axial conformation there is also to consider the 
hyperconjugation effect between the orbital containing unshared electron pair of the 
endocyclic heteroatom and the σ* orbital of the axial C-X bond. This causes the molecule 
to align the donating lone pair of electrons antiperiplanar to the σ* orbital lowering the 
overall energy of the system and causing more stability.  
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Therefore the sum of the two effects, the hyperconjugation and the arrangement of 
dipoles, justify the anomeric effect and thus the greater stability of C(1) electronegative 
group in axial position rather than in equatorial. 
 
 
 
 
Fig. 2.7: Rappresentation of the dipole minimization and hyperconjugation, which justify the anomeric 
effect. 
 
The anchimeric assistance instead is closely related to the presence of a substituent in 
C(2), which can influence the reaction mechanism, conducting to a specific 
stereochemistry. In our case the substituent in C(2) of the  α-TCA derivate (-)-2.3  is a 
benzoyl group. This group is directly involved in the glycosylation through the lone pair 
electrons of the carbonyl oxygen, that interact with the C(1) reaction centre. In particular, 
the axial orientation of the benzoyl is crucial in the obtainment of the α-anomer as only 
reaction product, thanks to the formation of the intermediate 2.3b which can be attacked 
only from the α-face (Scheme 2.19). 
 
 
 
 
 
 
Scheme 2.19: Effect of anchimeric assistance on the stereoselectivity glycosylation reaction. 
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Apart from the anchimeric assistance the general mechanism of the glycosylation proceed 
through an SN1 reaction with the formation of a carbenio ion. This mechanism is 
promoted by the presence of a quite polar solvent as CH2Cl2 and a quite strong Lewis 
acid as TMSOTf. The Lewis acid is necessary for the activation of the TCA derivate (-)-
2.3, encouraging the release of the trichloroacetamide (CCl3CONH2), which as previously 
mentioned acts as driving force of the reaction. While the dichloromethane provides the 
complete solubility of the compounds, enhancing the α-stereoselectivity. In this 
conditions, after the release of trichloroacetamide, the TCA derivate (-)-2.3 is turned into 
a carbenio ion 2.3c, which is preferentially attacked from the α-axial face due to 
stereoelectronical factors. 
 
 
 
 
 
 
 
 
Scheme 2.20: Glycosylation by SN1 mechanism. 
 
Then, thanks to the anomeric effect which benefits thermodynamically the obtaining of 
the α- product, and to the anchimeric assistance of the benzoyl group, that intervenes in 
the reaction mechanism through the formation of an intermediate, attachable only from 
the α-face, the reaction balance is totally moved toward the formation of the α-product (-
)-2.29. 
The fully-O-protected pseudo-disaccharide (-)-2.29 obtained from the glycosylation 
reaction must be completely deprotected to obtain the final product (+)-2.14. However, 
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the reducing and nonreducing moieties of the pseudo-disaccharide are protected with 
orthogonal groups, so they could be removed under different conditions. In particular, the 
nonreducing moiety presents all the hydroxyls protected with benzoyl groups, easy to 
remove in basic condition. The reducing moiety instead, presents the C(3) and C(4) 
hydroxyls protected as benzyl ethers, stable to saponification and removable under 
reducing conditions. Therefore, we can choose the sequence of deprotection in order to 
obtain the product with satisfactory yield. Actually for this choice, we relied on the past 
experience acquired during the previous synthesis of the antagonist (+)-2.1a in our 
laboratory. Thus, the deprotection sequence adopted was that already illustrated, which 
expected a first catalytic reduction to remove the benzyl groups of the reducing moiety, 
followed by a saponification to remove the remaining benzoyl groups of the nonreducing   
moiety. 
The hydrogenation was carried out solubilizing the fully-O-protected pseudo-
disaccharide (-)-2.29 in a mixture 4:1 MeOH/DMF adding Pd/C 10% as catalyst; the 
reaction flask was thus saturated with hydrogen atmosphere for all the night at room 
temperature. In the mixture MeOH/DMF, the methanol was present in a larger amount as 
solvent of the reaction, while a little amount of DMF was added to promote the complete 
solubilization of the starting material. After work-up was recovered the partially-O-
deprotected pseudomannobioside (-)-2.30. The subsequent 1H-NMR analysis showed that 
the obtained product did not have an adequate purity degree to enable him to proceed 
directly with the next saponification step. Thus, it was necessary find a suitable 
purification technique for our substrate. However, this task was very complex due to the 
small amounts and to the polarity of the partially-O-deprotected pseudomannobioside (-
)-2.30, which have not allowed the use of the common purification strategies as the flash 
chromatography.  
To begin we tried with a trituration of the compound in diisopropyl ether, with the aim to 
avoid losing further product during the use of more complex strategies. This particular 
technique is based on the use of solvents in which the product is not soluble. The purpose 
is represented by the elimination of the solvent, which thus contains the impurities, while 
the precipitate compound (in our case as yellow solid) is easily recovered. Anyway, after 
the application of this trituration was observed a slight improvement in the purity degree, 
even if not such to allow the continuation of the synthetic pathway. We thus opted for try 
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with another technique, the preparative TLC, which is more efficient in the purification, 
but at the same time could lead to a lower yield due to the interactions between the quite 
polar pseudo-disaccharide (-)-2.30 and the silica of the TLC. They were tested different 
types of eluent mixtures with different polarity in order to find the more suitable in our 
case, obtaining a better separation and a better yield of the pseudomannobioside (-)-2.30. 
The selected mixture was Ethyl acetate/Acetone 1:1 plus the 0.1% of methanol, this quite 
polar mixture allowed to obtain the partially-O-deprotected pseudomannobioside (-)-2.30 
with a good purity degree and despite everything also with a good yield (55%). 
The tetra-O-benzoyl pseudo-disaccharide (-)-2.30, as previously seen, was subjected to a 
saponification with the aim to remove the remaining benzoyl groups. The procedure 
utilized expects the solubilization of the pseudomannobioside (-)-2.30 in methanol 
followed by the adding of the right amount of a freshly prepared solution of sodium 
methoxide (MeONa) in MeOH 0.33M. The fresh solution was prepared adding the 
metallic sodium, properly weighed, in the right volume of methanol. The reaction was 
stirred overnight and then was quenched adding a weakly acidic resin, the Amberlite® 
IRC-50 in order to neutralize the basic pH of the reaction mixture. The final product was 
thus evaporated and subjected to an 1H-NMR analysis, which confirmed the obtaining of 
the desired product, indeed in the spectrum it was not highlighted the presence of signals 
related to the aromatic hydrogens. However, in some cases the normal reaction time was 
not enough as to ensure the complete deprotection of the benzoyl groups, and in these 
cases the 1H-NMR spectra show   in addition to the deprotected product also some signals 
in the aromatic area attributable to benzoyl groups. 
 A probable justification for this incomplete saponification could be, as reported in 
literature[51], the slower reactivity of axial groups respect to the equatorial ones. In fact, 
for compounds with a chair conformation subjected to saponification reactions an 
equatorial substituent is less hindered than an axial one and so is more reactive. 
 The hydrolysis of ester groups proceed through nucleophilic addition to a carbonyl 
carbon with subsequent formation of a tetrahedral complex as reaction intermediate. This 
further increases the effective bulk of the ester group and at the same time imparts a 
negative charge to it, increasing the solvation degree. Thus, the steric hindrance of the 
ester group becomes markedly greater in the transition state than in the ground state.  
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Scheme 2.21: Saponification mechanism for axial and equatorial ester groups. 
 
Consequently, the 1,3-diaxial interactions already present in the ground state become 
even stronger in the transition state. As a result, the difference in free energy between 
the axial and equatorial positions become greater in the transition state compared to the 
ground state, and this explains because the axial groups have a slower rate of reaction. 
 
 
Fig. 2.8: Energy diagram which highlights the difference between equatorial and axial groups 
reactivity under steric hindrance. 
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In those cases in which the saponification was incomplete, we decided to subject the 
partially deprotected disaccharide to another round of saponification, always utilizing a 
freshly prepared solution of MeONa. After this second saponification the 1H-NMR 
spectrum did not highlight the presence of signals related to benzyl groups, and the other 
analysis made (13C-NMR, 1H-1H COSY, DEPT-135) confirmed the obtainment of the 
totally deprotected pseudomannobioside (+)-2.14 as only product. Thus, despite this 
reactivity problem, with two subsequent saponification we were able to deprotect all the 
pseudomannobioside possessed. 
The 6-deoxy carba mannobioside (+)-2.14 obtained represents the final product of our 
synthetic pathway, and will be tested in order to evaluate its inhibitory activity toward the 
DC-SIGN receptor. For this reason the final pseudomannobioside was crystallized in 
diisopropyl ether to obtain a solid, more easily manageable and storable, ready thus to be 
sent to professor Frank Fieschi of the Institut de Biologie Structurale-Jean-Pierre Ebel, in 
Grenoble (France) for the enzymatic assays. 
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3. EXPERIMENTAL 
 
General procedures. 
All reactions were performed in flame-dried modified Schlenk (Kjeldahl shape) flasks 
fitted with a glass stopped or rubber septa under a positive pressure of Argon. Air and 
moisture-sensitive liquids and solutions were transferred via syringe. Organic solutions 
were dried on MgSO4 and concentrate by a rotary evaporator below 40°C al ca. 25 Torr. 
Flash chromatography was performed employing 230-400 mesh silica gel. Analytical 
TLC was performed on Alugram SIL G/UV254 silica gel sheets (Macherey_Nagel) with 
detection by 0.5% phosphomolybdic acid solution in 95% EtOH. 
 
Materials. 
MeONa, 0.5 M KHMDS in THF, 1.0 M TBAF in THF, 1 M LHMDS in THF, MeOH, 
(iPr)2O, tri-O-acetyl-D-glucal, Ph3PMeI, BnBr, TBAI, 1,3-dichlorobenzene, AP 100 
Silicone oil, LiAlH4, Cu(OTf)2, 70% MCPBA, 10% Pd-C, 60% mineral oil dispersion 
NaH, NaBH4, anhydrous CH2Cl2 over molecular sieves, anhydrous DMF over molecular 
sieves.  Imidazole, TBDMSCl, TMSOTf, molecular sieves AW300, TsCl, were purchased 
from Fluka and used without purification. 2-Iodoxybenzoic acid (IBX) was synthesized 
according to the literature methods. Toluene, Et2O and THF were distilled from 
sodium/benzophenone.  
 
Instrumentation. 
Infrared (IR) spectra were obtained using a Cary 600 Series FTIR spectrophotometer. 
Data are presented as frequency of absorption (cm-1). Specific rotations were measured 
with a digital polarimeter with a 1 dm cell. Proton and carbon-13 nuclear magnetic 
resonance (1H NMR and 13C NMR) spectra were recorded at 250 and 62.5 MHz 
respectively using a Bruker Advance 250 MHz spectrometer; chemical shifts are 
expressed in parts per million (δ scale) downfield from tetramethylsilane and refer to 
residual protium in the NMR solvent (CHCl3: δ 7.26; CD3OD: δ 3.31). Data are presented 
as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet 
and/or multiple resonances), integration, coupling constant in Hertz (Hz).  
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3.1 Synthesis of 6-deoxy carba mannobioside (+)-2.14 
 
6-O-tert-buthyldimethylsilyl-D-glucal 
 Imidazole (5.25g, 77.26 mmol, 2.0 equiv) was added to a solution of 
D-glucal (+)-2.16 (5.66 g, 38.63 mmol, 1.0 equiv) in anhydrous DMF 
(20.0 mL) and anhydrous THF (240.0 mL), cooled at 0 °C. Then 
TBDMSCl (8.77g, 58.47 mmol, 1.5 equiv) was then added. The 
resulting reaction mixture was stirred for 30 min, while the 
temperature rises till to r.t. Dilution with Et2O and evaporation of the washed (distilled 
water, saturated aqueous NaCl) organic solution afforded TBS-O-derivative (11.37 g, 
>99% yield), practically pure as an oil, which was directly utilized in the next step without 
any further purification.  
 
2.17: Rf = 0.51 (1:1 CH2Cl2/MeOH); FTIR (neat film) 3350, 3070, 2954, 2929, 2885, 
2857, 1649, 1463, 1254, 1052, 834, 777 cm-1. 1H NMR (CDCl3) δ 6.31 (dd, 1H, J = 6.0, 
1.8 Hz), 4.73 (dd, 1H, J = 6.0, 2.2 Hz), 4.30-4.23 (m, 1H), 4.05-3.87 (m, 2H), 3.86-3.69 
(m, 2H), 0.9 (s, 9H), 0.1 (s, 6H). 
 
3,4-Di-O-benzyl-6-(O- tert-buthyldimethylsilyl)-D-glucal 
A solution of trans-diol TBS-O-derivative 2.17 (6.0 g, 23.08 mmol, 
1.0 equiv) in anhydrous THF (20.0 mL) was added dropwise at 0°C 
to a suspension of 60% NaH in mineral oil, previously washed with 
hexane, (3.5 g, 85.40 mmol, 3.7 equiv) in anhydrous THF (80.0 mL) 
and the resulting reaction mixture was stirred for 30 min at room 
temperature. Subsequently BnBr (6.0 mL, 50.78 mmol, 2.2 equiv) and TBAI (430.0 mg, 
1.15 mmol, 0.05 equiv) were added to the solution and the resulting mixture was stirred 
overnight at room temperature. After dilution with Et2O and ice, evaporation of the 
washed (distilled water, saturated aqueous NaCl) organic solution afforded a crude 
product 2.18 (9.83 g, 96.8% yield), practically pure as a liquid. 
 
Experimental 
65 
 
2.18: Rf = 0.45 (9:1 hexane/AcOEt). 1H NMR (CDCl3) δ 7.42-7.26 (m, 10H), 6.38 (dd, 
1H, J = 6.1, 1.2 Hz), 4.86 (d, 1H, J = 11.2 Hz), 4.85-4.79 (m, 1H), 4.73 (d, 1H, J = 11.2 
Hz), 4.64 (d, 1H, J = 11.2 Hz) 4.57 (d, 1H, J = 11.2 Hz), 4.27-4.14 (m, 1H), 4.03-3.83 
(m, 4H), 0.9 (s, 9H), 0.06 (s, 6H). 
 
3,4-Di-O-benzyl-D-glucal 
The compound 2.18 (10.0 g, 22.73 mmol, 1.0 equiv) was solubilized 
in anhydrous THF (230.0 mL) and the reaction temperature was 
brought till 0°C. Then under stirring was added dropwise a 1.0 M 
solution of TBAF in THF (25.0 mL, 25.0 mmol, 1.1 equiv). After 4 h 
at room temperature the reaction mixture was diluted with Et2O, and 
the subsequent evaporation of the washed (saturated aqueous NaCl) and dried (MgSO4) 
organic phase afforded the crude product, which was subjected to flash chromatography 
(8:2 hexane/AcOEt) to afford the alcohol 2.19 (5.0 g, 67.6% yield), pure as a white solid. 
 
2.19: mp = 32-35 °C Rf = 0.18 (8:2 hexane/AcOEt); 
1H NMR (CDCl3) δ 7.41-7.27 (m, 
10H), 6.41 (dd, 1H, J = 6.1, 1.3 Hz), 4.94-4.88 (m, 1H), 4.87 (d, 1H, J = 11.6 Hz), 4.73 
(d, 1H, J = 11.6 Hz), 4.68 (d, 1H, J = 11.6 Hz), 4.57 (d, 1H, J = 11.6 Hz), 4.28-4.17 (m, 
1H), 3.99-3.91 (m, 1H), 3.90-3.75 (m, 3H). 
 
2-Formyl-3,4- di-(benzyl)-3,4-dihydro-2H-pyrane[43] 
IBX[45] (3.66 g, 13.06 mmol, 3.0 equiv) was added to a solution of 
primary alcohol 2.19 (1.42 g, 4.35 mmol, 1.0 equiv) in AcOEt (100.0 
mL) and the reaction mixture was stirred overnight at 75 °C. The 
reaction mixture was then filtered on celite® pad and evaporated, 
affording the pure aldehyde 2.20 (1.41 g, >99% yield), as an oil, 
which was used in the next step without any further purification. 
 
2.20:  Rf : 0.29 (7:3 hexane/AcOEt); [α]20D  +10.20 (c 1.12, CHCl3); 1H NMR (CDCl3) δ 
9.55 (s, 1H), 7.42-7.12 (m, 10H), 6.68 (d, 1H, J = 6.3 Hz), 5.16-4.98 (m, 1H), 4.81-4.49 
(m, 3H), 4.38 (s, 2H), 4.19-3.98 (m, 1H), 3.88-3.69 (m, 1H) 
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1,5-Anhydro-di-O-(benzyl)-2,6,7-trideoxy-D-arabino-Hept-1,6-Dienitol[43] 
A solution 1.0 M LHMDS in THF (6.05 mL, 6.05 mmol, 1.5 equiv) 
was added dropwise to a solution of Ph3PMe
+I- (2.61g, 6.45mmol, 1.6 
equiv) in anhydrous THF (25.0 mL) at -78 °C. The reaction mixture 
was stirred for 30 min at the same temperature and for 1 h at 0 °C, 
after that was cooled again at -78 °C. A solution of aldehyde 2.20 
(1.31 g, 4.03 mmol, 1.0 equiv) in anhydrous THF (13.8 mL) was added dropwise to  the 
reaction mixture and then was stirred at room temperature for 3 h. Dilution with Et2O and 
a subsequent filtration on Celite® pad afforded an organic phase, which was washed with 
three different aqueous solutions (saturated aqueous NH4Cl, saturated aqueous NaHCO3, 
and saturated aqueous NaCl), dried (MgSO4) and then evaporated. The crude product thus 
obtained was filtered again on Florisil®-silica gel pad, eluting with three hexane/AcOEt 
mixtures at different concentration (7:3, 1:1, 3:7). Evaporation of the first filtered mixture 
afforded only the olefin (-)-2.21, practically pure as an oil (0.878 g, 67.6% yield), used 
directly in the next step without any purifications.  
 
(-)-2.21:  Rf = 0.22 (9:1 hexane/AcOEt); [α]20D -34.7 (c 1.1, CHCl3);  1H NMR (CDCl3) δ 
7.45-7.28 (m, 10H), 6.42 (dd, 1H, J = 6.1, 1.2 Hz), 6.1 (ddd, 1H, J = 17.1, 10.6, 6.4 Hz), 
5.44 (dt, 1H, J = 17.1, 2.9, 1.4 Hz), 5.31 (dt, 1H, J = 10.6, 2.9, 1.4 Hz), 4.89 (dd, 1H, J = 
6.1, 2.7 Hz), 4.79 (d, 1H, J = 11.2 Hz), 4.69 (d, 1H, J = 11.2 Hz), 4.65 (d, 1H, J = 11.7 
Hz), 4.58 (d, 1H, J = 11.7 Hz), 4.34 (dd, 1H, J = 8.1, 6.7 Hz), 4.21 (ddd, 1H, J = 6.0, 2.7, 
1.6 Hz), 3.61 (dd, 1H, J = 8.4, 6.0 Hz); 13C NMR (CDCl3) δ 144.7, 138.6, 138.3, 134.5, 
128.6, 128.2, 127.9, 127.8, 118.5, 100.5, 78.5, 78.2, 75.6, 74.0, 70.9.  
 
3,4-Di-O-(benzyl)-5a-carba-D-glucal[43]  
The olefin (-)-2.21 (0.751 g, 2.33 mmol, 1 equiv) was solubilized in 
1,3 dichlorobenzene (3.47 mL) and the solution obtained was 
immersed into a warmed bath at 240° C, with AP 100 Silicone oil 
(Aldrich), for 1 h and 30 minutes. After cooling, the reaction mixture 
was added to a solution of NaBH4 (0.132 g, 3.50 mmol, 1.5 equiv) in 
2:1 THF/EtOH (3.86 mL) and stirred at room temperature for 20 minutes. The subsequent 
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dilution with Et2O led us to obtain an organic solution, which was washed (saturated 
aqueous NaCl), dried (Na2SO4) and finally evaporated, affording a crude product. This 
latter was then subjected to a flash chromatography with an 8:2 hexane/AcOEt mixture 
to obtain a primary alcohol 2.23 (0.500 g, 66.2% yield), pure as a liquid. 
 
2.23: Rf = 0.25 (7:3 hexane/AcOEt); FTIR (neat film) 3428, 3063, 3029, 2870, 1496, 
1454, 1026, 738, 695. 1H NMR (CDCl3) δ 7.50-7.27 (m, 10H), 5.85-5.63 (m, 2H), 4.99 
(d, 1H, J = 11.3 Hz), 4.74 (d, 1H, J = 11.3 Hz), 4.64 (d, 1H, J = 11.2 Hz), 4.24 (ddd, 1H, 
J = 7.1, 2.7, 1.4 Hz), 3.71-3.51 (m, 3H), 2.61 (dd, J = 8.0, 4.0 Hz), 2.13-1.74 (m, 2H). 13C 
NMR (CDCl3) δ 138.4, 131.0, 129.5, 127.8, 127.5, 125.9, 82.0, 81.2, 74.4, 71.3, 65.4, 
40.5, 29.8, 28.1. 
 
3,4-Di-O-benzyl-6-O-tosyl-5a-carba-D-glucal 
Tosyl chloride (TsCl) (0.284 g, 1.49 mmol, 1.3 equiv) was added to 
a solution of primary alcohol 2.23 (0.371 g, 1.14 mmol, 1 equiv) in 
anhydrous pyridine (4 mL) at 0° C. The reaction mixture was stirred 
for 18 h at room temperature and then directly co-evaporated with 
toluene, affording  the crude product, which was subjected to a flash 
chromatography with a 8:2 CH2Cl2/hexane mixture to obtain the tosylate (-)-2.24 (0.400 
g, 73.10%  yield), pure as a yellow liquid. 
 
(-)-2.24: Rf = 0.24 (8:2 hexane/AcOEt); [α]20D -2.51 (c 1.26, CHCl3). FTIR (neat film) 
3031, 2903, 1359, 1175, 1094, 926, 813, 666. 1H NMR (CDCl3) δ 7.75 (d, 2H, J = 8.3 
Hz), 7.35-7.27 (m, 10H), 7.21-7.15 (m, 2H), 5.76-5.63 (m, 2H), 4.84 (d, 1H, J = 10.9 Hz), 
4.67 (d, 1H, J = 11.6 Hz), 4.60 (d, 1H, J = 11.6 Hz), 4.48 (d, 1H, J = 10.9 Hz), 4.21 (dd, 
1H, J = 9.2, 5.2 Hz), 4.17-4.09 (m, 2H), 3.56 (dd, 1H, J = 9.7, 7.1 Hz), 2.41 (s, 3H), 2.26-
2.07 (m, 3H). 13C NMR (CDCl3) δ 145.0, 138.5, 130.0, 128.6, 128.1, 128.0, 126.3, 80.9, 
78.6, 74.4, 71.5, 70.7, 38.4, 28.0, 21.8. 
 
 
 
Experimental 
68 
 
3,4-Di-O-benzyl-6-deoxy-5a-carba-D-glucal 
A solution of tosylate (-)-2.24 (0.262 g, 0.548 mmol, 1.0 equiv) in 
anhydrous Et2O (22.5 mL) was treated with LiAlH4 (0.183 g, 4.86 
mmol, 8.8 equiv) at 0 °C and the reaction mixture was stirred 5 h at 
the same temperature. After dilution with Et2O, at the reaction 
mixture was added dropwise water and 10% aqueous NaOH until the 
formation of a white precipitate, and then magnesium sulfate (MgSO4). The subsequent 
filtration and evaporation of the decanted solution afforded the methyl-substituted olefin 
(+)-2.25 (0.155 g, 91.80% yield), pure as a yellow oil.  
 
(+)-2.25: Rf = 0.49 (8:2 hexane/AcOEt); [α]20D +10.2 (c 0.16, CHCl3). FTIR (neat film) 
3064, 3030, 2951, 2888, 1496, 1454, 1101, 735, 696. 1H NMR (CDCl3) δ 7.42-7.27 (m, 
10 H), 5.81-5.62 (m, 2H), 4.93 (d, 1H, J = 11.0 Hz), 4.70 (s, 2H), 4.67 (d, 1H, J = 11.0 
Hz), 4.21-4.13 (m, 1H), 3.32 (dd, 1H, J = 10.6, 7.6 Hz), 2.20-2.14 (m, 1H), 1.95-1.76 (m, 
2H), 1.09 (d, 3H, J = 6.2 Hz). 13C NMR (CDCl3) δ 132.7, 128.7, 128.6, 128.2, 128.1, 
127.9, 127.7, 119.1, 75.0, 74.0, 53.7, 42.6, 34.2, 27.5, 14.5.  
 
Reaction of methyl-substituted olefin (+)-2.25 with MCPBA 
The methyl-substituted olefin (+)-2.25  (0.127 g, 0.412 mmol, 1 equiv) was solubilized 
in anhydrous CH2Cl2 (12.7 mL), thus was added MCPBA (0.203 g, 0.825 mmol, 2 equiv) 
to the reaction mixture, which was stirred 18 h at room temperature. Dilution with 
CH2Cl2, followed by washing with three aqueous solutions (Na2S2O3 aqueous solution 
10%, saturated aqueous NaHCO3, saturated aqueous NaCl) and drying (MgSO4) of the 
organic phase afforded a crude reaction product, consisting of a 6:4 mixture of the 
diastereoisomeric epoxides (+)-2.26β and (+)-2.26α. Purification by flash 
chromatography with a 9:1 hexane/AcOEt mixture afforded the pure epoxides (+)-2.26β  
and (+)-2.26α. 
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3,4-Di-O-benzyl-6-deoxy-1,2-anhydro-5a-carba-α-D-
glucopyranose: 
(0.0773 g, 57.8% yield), pure as a solid: mp: 62-65 °C; Rf = 0.40 (8:2 
hexane/AcOEt); [α]20D +6.77 (c 2.17, CHCl3). 1H NMR (CDCl3) δ 
7.39-7.22 (m, 10H), 4.79 (d, 1H, J = 11.0 Hz), 4.76 (d, 1H, J = 11.3 Hz), 4.65 (d, 1H, J = 
11.3 Hz), 4.54 (d, 1H, J = 11.0 Hz), 3.70 (d, 1H, J = 7.9 Hz), 3.15-3.09 (m, 2H), 2.96 (dd, 
1H, J = 10.8, 7.9 Hz), 2.22-2.10 (m, 1H), 1.66-1.39 (m, 2H), 0.93 (d, 3H, J = 6.3 Hz). 13C 
NMR (CDCl3) δ 138.9, 138.0, 128.7, 128.5, 128.1, 127.7, 84.5, 80.6, 74.8, 72.8, 54.5, 
52.9, 33.1, 27.5, 17.8. 
3,4-Di-O-benzyl-6-deoxy-1,2-anhydro-5a-carba-β-D-
mannopyranose:  
(0.0387 g, 29.0% yield), pure as a solid: mp: 28-31 °C; Rf = 0.26 (8:2 
hexane/AcOEt); [α]20D +14.9 (c 0.99, CHCl3). 1H NMR (CDCl3) δ 
7.39-7.27 (m, 10H), 4.88 (d, 1H, J = 10.7 Hz), 4.83 (s, 2H), 4.58 (d, 1H, J = 10.7 Hz), 
3.80 (dd, 1H, J = 8.2, 1.9 Hz), 3.36-3.27 (m, 2H), 3.24-3.19 (m, 1H), 1.72-1.55 (m, 3H), 
0.98 (d, 3H, J = 6.0 Hz). 13C NMR (CDCl3) δ 138.8, 138.7, 128.6, 128.3, 128.1, 127.8, 
82.3, 81.7, 75.7, 72.6, 55.9, 53.8, 34.7, 32.2, 17.7. 
 
(2-Azidoethyl)-3,4-di-O-benzyl-6-deoxy-5a-carba-α-D-mannopyranoside 
Epoxide (+)-2.26β (0.0692 g, 0.213 mmol, 1 equiv) was 
solubilized in a solution of 1.3 M 2-azido-1-ethanol in 
CH2Cl2 (0.657 mL, 0.854 mmol, 4.0 equiv) and Cu(OTf)2 
(0.0232 g, 0.064 mmol, 0.3 equiv) was subsequently 
added. The reaction mixture was stirred for 18 h at room 
temperature. Dilution with CH2Cl2 and evaporation of the washed (saturated aqueous 
NaHCO3, saturated aqueous NH4Cl and saturated aqueous NaCl) and dried (Na2SO4) 
organic solution afforded the ring opening product (+)-2.15 (0.079 g, 90% yield), pure as 
a yellow syrup. 
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(+)-2.15: Rf = 0.29 (7:3 hexane/AcOEt); [α]20D +2.04 (c 0.98, CHCl3); FTIR (neat) ν 3461, 
2924, 2870, 2104, 1101, 1053. 1H NMR (CDCl3) δ 7.40 – 7.21 (m, 10H), 4.88 (d, 1H, J 
= 10.9 Hz), 4.69 (q, 2H, J = 11.4 Hz), 4.60 (d, 1H, J = 10.9 Hz), 4.15 – 4.11 (m, 1H), 3.77 
(dd, 1H, J = 9.1, 3.2 Hz), 3.74 – 3.71 (m, 1H), 3.70 – 3.63 (m, 1H), 3.57 – 3.48 (m, 1H), 
3.38 – 3.20 (m, 3H), 2.52 (s, 1H), 1.99 – 1.83 (m, 1H), 1.76 (dt, 1H, J = 14.3, 2.8 Hz), 
1.65 – 1.45 (m, 1H), 1.04 (d, 3H, J = 6.5 Hz). 13C NMR (CDCl3) δ 139.11, 138.48, 128.62, 
128.47, 128.10, 128.08, 127.97, 127.64, 83.06, 82.11, 77.00, 75.26, 72.73, 69.60, 68.19, 
50.98, 31.63, 31.45, 18.28, 1.16. 
 
(2-Azidoethyl)-2-O-[2’,3’,4’,6’-tetra-O-benzoyl-α-D-mannopyranosyl]-3,4,-di-O-
benzyl-6-deoxy-5a-carba-α-D-mannopyranoside  
The glycosyl-donor trichloroacetimidate (-)-2.3 (0.178 g, 
0.240 mmol, 1.3 equiv) and the glycosyl-acceptor, the 
partially protected carbamannoside (+)-2.15 (0.076 g, 
0.185 mmol, 1 equiv) were dissolved in distilled toluene 
and dried for 2 h at the pump. The mixture was solubilized 
in dry CH2Cl2 (1.52 mL) and, after activation under 
vacuum, were added the molecular sieves AW 300. A solution of 0.1 M TMSOTf in 
CH2Cl2 (0.037 ml, 0.037 mmol, 0.2 equiv) was added to the reaction mixture at -20°C 
under argon atmosphere, and then the mixture was stirred at the same temperature for 1 
h. The reaction was worked-up by dilution with CH2Cl2 and adding of Et3N followed by 
a filtration on Celite® pad. Evaporation of the solvent afforded a crude product, which 
was subjected to a flash chromatography with a 7:3 hexane/AcOEt mixture to obtain the 
O-protected pseudomannobioside (-)-2.29 (0.152 mg, 83.1% yield), pure as a white solid. 
 
(-)-2.29: Rf = 0.44 (8:2 hexane/AcOEt 4 developments); [α]20D  -80.0 (c 0.25, CHCl3); 
FTIR (neat) ν 3372, 3243, 2928, 2872, 2360, 2339, 2106, 1727, 1695, 1262. 1H NMR 
(CDCl3) δ 8.11 – 8.01 (m, 6H), 7.99 – 7.92 (m, 3H), 7.86 – 7.79 (m, 3H), 7.65 – 7.20 (m, 
14H), 7.19 – 7.01 (m, 4H), 6.01 (t, 1H, J = 9.8 Hz), 5.92 – 5.83 (m, 2H), 5.49 (d, 1H, J = 
1.5 Hz), 4.96 – 4.57 (m, 5H), 4.54 – 4.35 (m, 2H), 4.22 (s, 1H), 3.79 (dd, 1H, J = 9.2, 2.6 
Hz), 3.64 (s, 1H), 3.49 (m, 2H, J = 8.8, 6.3, 2.4 Hz), 3.37 – 3.22 (m, 1H), 3.19 – 3.10 (m, 
2H), 1.96 – 1.65 (m, 3H), 1.10 (d, 3H, J = 6.5 Hz). 13C NMR (CDCl3) δ 166.30, 165.71, 
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165.70, 165.21, 139.10, 138.63, 133.61, 133.52, 133.31, 130.03, 129.97, 129.93, 129.86, 
129.57, 129.25, 129.06, 128.68, 128.61, 128.58, 128.45, 128.40, 127.76, 127.56, 127.49, 
127.43, 99.04, 82.94, 81.55, 76.08, 75.49, 73.10, 70.31, 70.11, 69.52, 67.90, 67.32, 63.38, 
50.86, 32.52, 31.94, 18.21. 
 
(2-Aminoethyl)-2-O-[2’,3’,4’,6’-tetra-O-benzoyl-α-D-mannopyranosyl]-6-deoxy-5a-
carba-α-D-mannopyranoside   
Pseudomannobioside (-)-2.29 (0.120 g, 0.122 mmol, 1 
equiv) was solubilized in a 4:1 MeOH/DMF mixture (6.0 
mL) and 10% Pd-c (0.123 g) was added. The reaction 
flask was saturated with hydrogen atmosphere (1 bar) at 
room temperature. After 18 h the mixture was diluted with 
MeOH and filtered through a Celite® pad. The 
evaporation of the solvent afforded a crude reaction product, which was subjected to a 
purification step by means preparative TLC with 1:1 AcOEt/Acetone plus 1% of MeOH 
mixture as eluent, to afford the 1,2-pseudomannobioside (-)-2.30 (0.056 g, 58.8% yield), 
pure as a yellow solid.  
 
(-)-2.30: Rf = 0.15 (9:1 CH2Cl2/MeOH); [α]20D -28.4 (c, MeOH); FTIR (neat) ν 3354, 
2924, 2360, 2340, 1725, 1261. 1H NMR (MeOD) δ 8.16 – 7.90 (m, 6H), 7.80 – 7.20 (m, 
14H), 6.11 (t, 1H, J = 9.9 Hz), 5.94 – 5.88 (m, 1H), 5.82 (dd, 1H ,J = 10.2, 3.2 Hz), 5.49 
(d, 1H, J = 1.7 Hz), 4.79 – 4.73 (m, 1H), 4.52 (d, 1H, J = 10.5 Hz), 4.25 (s, 1H), 3.85 (s, 
1H), 3.79 – 3.54 (m, 4H), 3.47 (t, J = 9.3 Hz, 1H), 3.06 (s, 1H), 1.99 – 1.95 (m, 1H), 1.82 
– 1.52 (m, 3H), 1.14 (d, 3H, J = 6.1 Hz). 13C NMR (MeOD) δ 167.52, 167.02, 166.84, 
166.54, 134.80, 134.76, 134.59, 134.55, 131.13, 130.78, 130.73, 130.71, 130.62, 130.53, 
130.31, 130.28, 129.86, 129.79, 129.66, 129.49, 101.26, 80.50, 78.34, 76.62, 74.04, 
71.69, 71.28, 70.75, 68.23, 64.06, 63.98, 33.27, 33.09, 30.75, 18.35. 
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(2-Aminoethyl)-2-O-(α-D-mannopyranosyl)-6-deoxy-5a-carba-α-D-
mannopyranoside 
A fleshly prepared solution 0.33 M of MeONa (0.1 mL, 
0.033 mmol,) in MeOH was added to a solution of 1,2-
pseudomannobioside (-)-2.30 (0.0097 g, 0.0124 mmol, 
1.0 equiv) in MeOH (0.2 mL) and the reaction mixture 
was stirred for 12 h at room temperature. The reaction was 
worked-up by dilution with MeOH and subsequent adding 
of weakly acidic Amberlite® IRC-50 until pH=7. The 
beads were filtered off and the solution was evaporated affording the fully O-deprotected 
1,2-pseudomannobioside (0.0045 g, 99% yield), pure as a yellow oil, which was subjected 
to a crystallization in presence of (i-Pr)2O. Removal of the surnatant and drying of the 
precipitate, afforded the product pure as a yellow solid.  
 
(+)-2.14: Rf = 0.15 (1:1 CH2Cl2/MeOH); [α]20D +26.5 (c 0.98, MeOH); FTIR (neat) ν 
3351, 2924, 2506, 1634, 1053, 1023. 1H NMR (MeOD) δ 5.05 (d, 1H, J = 1.6 Hz), 4.07 
(t, 1H, J = 2.9 Hz), 3.98 (dd, 1H J = 3.1, 1.8 Hz), 3.90 (s, 1H), 3.85 (s, 1H), 3.81 – 3.50 
(m, 12H), 3.25 (t, 2H J = 9.8 Hz), 3.12 (t, 2H J = 4.6 Hz), 1.88 – 1.42 (m, 5H), 1.03 (d, 
3H J = 6.3 Hz). 13C NMR (CDCl3) δ 104.08, 79.84, 78.37, 76.74, 75.57, 73.99, 72.51, 
71.81, 68.76, 65.86, 63.29, 40.80, 33.13, 33.07, 30.77, 18.39. 
 
Synthesis of a 1.3 N solution of 2-azido-1-ethanol in CH2Cl2 
2-chloro-1-ethanol (1.75 mL, 26.07 mmol) was 
added to a solution of NaN3 (2.0 g, 30.77 mmol, 1.18 
equiv) in distilled H2O (8.0 mL) and the resulting 
reaction mixture was stirred at room temperature for 
1 h, and then heated at 70°C for 3 days. After cooling the reaction mixture was diluted 
with brine and the aqueous phase was extracted 3 times with CH2Cl2. The combined 
organic extracts were dried over Na2SO4 and concentrated under vacuum (rotating 
evaporator) until about 20 mL. An analytical amount of this solution was completely 
evaporated at the pump, and the resulting liquid residue examined by 1H NMR analysis. 
Experimental 
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The concentrate solution of 2-azido-ethanol in CH2Cl2 was used as the reagent in the 
corresponding glycosylation reaction. 
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4. APPENDIX 
 
4.1 1H-NMR Spectra of the new compounds synthesized: 
The initial products obtained in this thesis project were already synthesized in our 
laboratory and then already characterized. 
Here were reported only the 1H-NMR spectra of the new compounds obtained, not 
previously characterized. 
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